Robert A. Wolff, M.D.
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
About Dr. Wolff
Dr. Wolff is a Professor of Medicine in the Department of GI Medical Oncology at MD Anderson Cancer Center. He is also the Deputy Division Head, Clinical and Educational Affairs in the Division of Cancer Medicine.
Dr. Wolff graduated from Albany Medical College in Albany, New York and completed his residency and fellowship training in Hematology/Oncology at Duke University Medical Center. He joined the faculty of MD Anderson Cancer Center in 1997, where his research has focused on the treatment of pancreatic cancer.
He has been a collaborator with surgical oncologists, radiation oncologists, and laboratory researchers in trying to understand the causes of pancreatic cancer and to design better treatment strategies for resectable, locally advanced, and metastatic pancreatic cancer.
Present Title & Affiliation
Primary Appointment
Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Deputy Division Head, Clinical and Educational Affairs, Department of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Sheikh Zayed Bin Sultan Al Nahyan Distinguished University Chair of Medical Oncology, Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1986 | Albany Medical College, Albany, New York, US, MD |
| 1979 | Colgate University, Hamilton, New York, US, Mathematical Economics, BA |
Postgraduate Training
| 1989-1992 | Fellowship Training Hematology/Oncology, Duke University Medical Center, Durham, North Carolina |
| 1986-1989 | Clinical Residency, Internal Medicine, Duke University Medical Center, Durham, North Carolina |
| 1983-1984 | NIH-Summer Student Fellowship Biochemistry/Protein Purification, Albany Medical College, Albany, New York |
| 1981-1982 | Graduate Studies In vitro fertilization / Reproductive Physiology, Division of Reproductive Biology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland |
Board Certifications
| 1993 | Medical Oncology |
| 1992 | Hematology |
| 1989 | Internal Medicine - Lifetime |
Experience & Service
Academic Appointments
Associate Professor, Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2003 - 2008
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, 1997 - 2003
Associate in Medicine, Duke University Medical Center, Durham, NC, 1992 - 1997
Administrative Appointments/Responsibilities
Program Director, ad interim, Department of Hematology/Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - 2025
Division Director for Safety Operations and Professionalism for DoCM Quality Assessment and Performance Improvement, Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, 2019 - Present
Department Chair ad interim, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2017
Department Chair ad interim, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2015
Chair, Committee for Professional Education and Training, Sheikh Khalifa Institute for Personalized Cancer Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2013 - Present
Department Chair ad interim, Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2012 - 2013
Deputy Division Head, Clinical and Educational Affairs, Department of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2006 - Present
Deputy Chairman for Clinical Affairs, Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2003 - 2006
Director, Educational Programs, Department of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 1999 - 2019
Other Appointments/Responsibilities
Chair, American Society of Clinical Oncology Training Programs Subcommittee, Chicago, IL, 2013 - 2014
Member, American Society of Clinical Oncology Cancer Education Committee, Chicago, IL, 2012 - 2013
Scientific Advisory Board Member, Sheikh Ahmed Center for Pancreatic Cancer Research, Houston, TX, 2011 - Present
IPCT Liaison Member, Institute for Personalized Cancer Therapy (IPCT), Houston, TX, 2011 - Present
Member, Data Monitoring Committee, Amplimed Corporation, Tucson, Arizona, 2008 - 2010
Consultant, Center for Global Oncology, Doha, Qatar, 2008 - Present
Consultant, American Society of Clinical Oncology, Chicago, IL, 2006 - Present
Consultantships, FDA Consultant, Bethesda, MD, 2005 - 2005
Consultantships, FDA Consultant, Bethesda, MD, 2003 - 2003
Institutional Committee Activities
Committee Member, Promotion and Tenure Committee, 2021 - 2024
Member, Institutional Conflict of Interest (ICOI) Committee, 2018 - Present
Chair, Committee for Professional Education and Training of the Sheikh Khalifa Bin Zayed Al Nahyan Institute of Personalized Cancer Therapy, 2012 - Present
Voting Member, PRS Executive Council, 2010 - 2012
Member, Promotion and Tenure Committee, 2008 - 2011
Member, Patient Safety Committee, 2006 - Present
Alternate, Executive Committee of the Medical Staff, 2006 - Present
Member, Credentials Committee of the Medical Staff, 2004 - 2007
Member, Credentialing Committee of the Medical Staff, 2002 - 2004
Honors & Awards
| 2024 | The Charles A. Koller Lectureship, MD Anderson and Baylor College of Medicine Board Review in Hematology and Medical Oncology |
| 2019 | Clinical Education Excellence Award - Outstanding Program Director, The University of Texas MD Anderson Academy of Health Science Education (AHSE) |
| 2017 | Excellence in Education and Mentorship, MD Anderson Cancer Center |
| 2017 | PRS Samuel J. Hassenbusch, III, M.D. Leadership & Institutional Service Award, PRS and the L.I.S.A. Selection Committee - MD Anderson Cancer Center |
| 2014 | The 2014 Regents' Outstanding Teaching Award, University of Texas System |
| 2010 | Hematology/Oncology Fellowship Program Honorary Fellow, MD Anderson Cancer Center |
| 2009 | Faculty Educator of the Month, MD Anderson Cancer Center |
| 2007 | Gerald P. Bodey Award for Excellence in Education, MD Anderson Cancer Center Annual Faculty Recognition and Award Program |
| 2006 | Melvin Samuels Award for Excellence in Patient Care, MD Anderson Cancer Center Annual Faculty Recognition and Award Program |
| 2006 | Leadership in Education Award, Selected by Dr. Waun Ki Hong for outstanding leadership of the Hematology/Oncology Fellowship Program |
| 2003 | Hematology/Oncology Fellowship Program Teacher of the Year, MD Anderson Cancer Center |
| 2003 | Surgical Oncology Teacher of the Year, MD Anderson Cancer Center |
| 2001 | Best Doctors |
| 1992 | Trainee Investigator Award, AAP/ASCI/AFCR |
| 1992 | Physician Scientist Award, Public Health Service National Institutes of Health National Cancer Institute |
| 1991 | National Research Science Award, Public Health Service National Institutes of Health |
| 1985 | Alpha Omega Alpha, Theta Chapter, Albany Medical College |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Ahmed J, Knisely A, Torrado C, Stephen B, Yang Y, Song J, Alshawa A, Zarifa A, Jhingran A, Koay EJ, Morris VK, Javle M, Wolff RA, Meric-Bernstam F, Pant S, Rodon J, Naing A. A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies. Oncologist 30(3), 2025. e-Pub 2025. PMID: 40139261.
- Peddireddy AS, Huey R, Wolff RA, Lin K, Mitchell J, Scofield L, Jacob S, Nguyen DV, Rogers J, Portier S, Foo WC, Eng C, Morris VK. Clinicopathologic Features Associated with Survival for Immune Checkpoint Blockade in Patients with Metastatic Anal Cancer. Cancers (Basel) 17(6), 2025. e-Pub 2025. PMID: 40149273.
- Alshenaifi JY, Vetere G, Maddalena G, Yousef M, White MG, Shen JP, Vilar E, Parseghian C, Dasari A, Morris VK, Huey R, Overman MJ, Wolff R, Raghav KP, Willis J, Alfaro K, Futreal A, You YN, Kopetz S. Mutational and co-mutational landscape of early onset colorectal cancer. Biomarkers 30(1):64-76, 2025. e-Pub 2025. PMID: 39761813.
- Bhamidipati D, Johnson JR, Lin K, Pelicano H, Eng C, Huey R, Wolff RA, Halperin DM, Frumovitz MF, Wistuba II, Duose DY, Mallampati S, Luthra R, Morris VK. The Clinical Utility of a Next-Generation Sequencing-Based Approach to Detecting Circulating HPV DNA in Patients with Advanced Anal Cancer. Cancers (Basel) 17(2), 2025. e-Pub 2025. PMID: 39858090.
- Yousef M, Hurd MW, Yousef A, Ludmir EB, Pillai AB, Peterson J, Koay EJ, Albarouki S, Tzeng CW, Snyder R, Katz MHG, Wang H, Overman MJ, Maitra A, Pant S, Smaglo BG, Wolff RA, Yao J, Shen JP, Zhao D. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Oncologist 30(1), 2025. e-Pub 2025. PMID: 39014543.
- Yennurajalingam S, Valero V, Smalgo BG, Overman MJ, Dasari A, Wolff RA, Raghav KPS, Barcenas CH, Busaidy NL, Fellman B, Basen-Engquist K, Hess KR, Tripathy D, Bruera E. Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Preliminary Placebo-Controlled, Randomized, Double-Blind Trial. J Natl Compr Canc Netw 23(1), 2025. e-Pub 2025. PMID: 39773433.
- Yousef, M, Yousef, A, Chowdhury, S, Fanaeian, M, Knafl, M, Peterson, J, Zeineddine, MA, Alfaro, KD, Zeineddine, F, Goldstein, D, Hornstein, N, Dasari, NV, Huey, RW, Johnson, B, Serpas Higbie, V, Bent, AH, Kee, BK, Lee, MS, Morelli, MP, Morris, VK, Halperin, DM, Overman, MJ, Parseghian, C, Vilar Sanchez, E, Wolff, RA, Raghav, KS, White, MG, Uppal, A, Sun, R, Wang, W, Kopetz, S, Willis, JA, Shen, JY. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncology 10(11), 2024. e-Pub 2024. PMID: 39264607.
- Ludmir EB, Sherry AD, Fellman BM, Liu S, Bathala T, Haymaker C, Medina-Rosales MN, Reuben A, Holliday EB, Smith GL, Noticewala SS, Nicholas S, Price TR, Martin-Paulpeter RM, Perles LA, Lee SS, Lee MS, Smaglo BG, Huey RW, Willis J, Zhao D, Cohen L, Taniguchi CM, Koay EJ, Katz MHG, Wolff RA, Das P, Pant S, Koong AC, Tang C. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial. J Clin Oncol 42(32):JCO2400081, 2024. e-Pub 2024. PMID: 39102622.
- Balachandran Pillai A, Yousef M, Yousef A, Alfaro-Munoz KD, Smaglo BG, Willis J, Wolff RA, Pant S, Hurd MW, Maitra A, Wang H, Katz MHG, Prakash LR, Tzeng CD, Snyder R, Castelnovo LF, Chen A, Kravets A, Kudriavtseva K, Tarasov A, Kryukov K, Ying H, Shen JP, Zhao D. Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single-Institution Case Series. Cancers (Basel) 16(19), 2024. e-Pub 2024. PMID: 39410042.
- Taherian, M, Katz, MH, Prakash, L, Wei, D, Tong, YT, Lai, Z, Chatterjee, D, Wang, H, Kim, M, Tzeng, CD, Ikoma, N, Wolff, RA, Zhao, D, Koay, EJ, Maitra, A, Wang, H. The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Cancers 16(19), 2024. e-Pub 2024.
- Hassan MM, Li D, Han Y, Byun J, Hatia RI, Long E, Choi J, Kelley RK, Cleary SP, Lok AS, Bracci P, Permuth JB, Bucur R, Yuan JM, Singal AG, Jalal PK, Ghobrial RM, Santella RM, Kono Y, Shah DP, Nguyen MH, Liu G, Parikh ND, Kim R, Wu HC, El-Serag H, Chang P, Li Y, Chun YS, Lee SS, Gu J, Hawk E, Sun R, Huff C, Rashid A, Amin HM, Beretta L, Wolff RA, Antwi SO, Patt Y, Hwang LY, Klein AP, Zhang K, Schmidt MA, White DL, Goss JA, Khaderi SA, Marrero JA, Cigarroa FG, Shah PK, Kaseb AO, Roberts LR, Amos CI. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology 80(1):87-101, 2024. e-Pub 2024. PMID: 38381705.
- Till JE, McDaniel L, Chang C, Long Q, Pfeiffer SM, Lyman JP, Padrón LJ, Maurer DM, Yu JX, Spencer CN, Gherardini PF, Da Silva DM, LaVallee TM, Abbott C, Chen RO, Boyle SM, Bhagwat N, Cannas S, Sagreiya H, Li W, Yee SS, Abdalla A, Wang Z, Yin M, Ballinger D, Wissel P, Eads J, Karasic T, Schneider C, O'Dwyer P, Teitelbaum U, Reiss KA, Rahma OE, Fisher GA, Ko AH, Wainberg ZA, Wolff RA, O'Reilly EM, O'Hara MH, Cabanski CR, Vonderheide RH, Carpenter EL. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Nat Commun 15(1):5763, 2024. e-Pub 2024. PMID: 38982051.
- Chang E, Wong FCL, Chasen BA, Erwin WD, Das P, Holliday EB, Koong AC, Ludmir EB, Minsky BD, Noticewala SS, Smith GL, Taniguchi CM, Rodriguez MJ, Beddar S, Martin-Paulpeter RM, Niedzielski JS, Sawakuchi GO, Schueler E, Perles LA, Xiao L, Szklaruk J, Park PC, Dasari AN, Kaseb AO, Kee BK, Lee SS, Overman MJ, Willis JA, Wolff RA, Tzeng CD, Vauthey JN, Koay EJ. Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectr 8(3), 2024. e-Pub 2024. PMID: 38730548.
- Cass SH, Tzeng CD, Prakash LR, Maxwell J, Snyder RA, Kim MP, Huey RW, Smaglo BG, Pant S, Koay EJ, Wolff RA, Lee JE, Katz MHG, Ikoma N. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Ann Surg. e-Pub 2024. PMID: 38506042.
- Johnson, B, Morris, VK, Wang, X, Dasari, NV, Raghav, KS, Shen, JY, Lee, MS, Huey, RW, Parseghian, C, Willis, JA, Wolff, RA, Drusbosky, L, Overman, MJ, Kopetz, S. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling. Cancers 16(4), 2024. e-Pub 2024. PMID: 38398128.
- Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH, Sakellariou-Thompson D, Haymaker CL, Forget MA, Hwu P, Bernatchez C, Jazaeri AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer 12(2), 2024. e-Pub 2024. PMID: 38309721.
- Yousef A, Yousef M, Chowdhury S, Abdilleh K, Knafl M, Edelkamp P, Alfaro-Munoz K, Chacko R, Peterson J, Smaglo BG, Wolff RA, Pant S, Lee MS, Willis J, Overman M, Doss S, Matrisian L, Hurd MW, Snyder R, Katz MHG, Wang H, Maitra A, Shen JP, Zhao D. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. NPJ Precis Oncol 8(1):27, 2024. e-Pub 2024. PMID: 38310130.
- Mohamed YI, Lee SS, Demir T, Chamseddine S, Hu ZI, Xiao L, Elsayes K, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, LaPelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan M, Amin HM, Kaseb AO. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomark 41(1):83-91, 2024. e-Pub 2024. PMID: 39269823.
- Dansby, J, More, A, Zeineddine, MA, Yousef, A, Bent, AH, Dayyani, F, Wolff, RA, Overman, MJ, Shen, JY. Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma. Oncologist 28(12):e1303-e1305, 2023. e-Pub 2023. PMID: 37738316.
- Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
- Surana R, Gonzalez GN, Rogers J, Hong DS, Yap TA, Rodon J, Naing A, Wolff RA, Smaglo BG, Bernstam FM, Subbiah V, Pant S. Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials. J Gastrointest Cancer 54(4):1308-1315, 2023. e-Pub 2023. PMID: 37119430.
- Taniguchi CM, Frakes JM, Aguilera TA, Palta M, Czito B, Bhutani MS, Colbert LE, Abi Jaoude J, Bernard V, Pant S, Tzeng CD, Kim DW, Malafa M, Costello J, Mathew G, Rebueno N, Koay EJ, Das P, Ludmir EB, Katz MHG, Wolff RA, Beddar S, Sawakuchi GO, Moningi S, Slack Tidwell RS, Yuan Y, Thall PF, Beardsley RA, Holmlund J, Herman JM, Hoffe SE. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol 24(12):1387-1398, 2023. e-Pub 2023. PMID: 38039992.
- Yousef A, Yousef M, Chowdhury S, Abdilleh K, Knafl M, Edelkamp P, Alfaro-Munoz K, Chacko R, Peterson J, Smaglo BG, Wolff RA, Pant S, Lee MS, Willis J, Overman M, Doss S, Matrisian L, Hurd MW, Snyder R, Katz MHG, Wang H, Maitra A, Shen JP, Zhao D. Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Res Sq, 2023. e-Pub 2023. PMID: 37609177.
- Rogers, JE, Sirisaengtaksin, A, Leung, M, Morris, VK, Xiao, L, Huey, RW, Wolff, RA, Eng, C, Vauthey, JN, Tzeng, CD, Johnson, B. Hepatic Metastasectomy in Squamous Cell Carcinoma of the Anal Canal. Cancers 15(15), 2023. e-Pub 2023. PMID: 37568706.
- Sans M, Chen Y, Thege FI, Dou R, Min J, Yip-Schneider M, Zhang J, Wu R, Irajizad E, Makino Y, Rajapakshe KI, Hurd MW, León-Letelier RA, Vykoukal J, Dennison JB, Do KA, Wolff RA, Guerrero PA, Kim MP, Schmidt CM, Maitra A, Hanash S, Fahrmann JF. Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an early metabolic alteration. bioRxiv, 2023. e-Pub 2023. PMID: 37645752.
- Sans M, Makino Y, Min J, Rajapakshe KI, Yip-Schneider M, Schmidt CM, Hurd MW, Burks JK, Gomez JA, Thege FI, Fahrmann JF, Wolff RA, Kim MP, Guerrero PA, Maitra A. Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential. Cancer Discov 13(8):1844-1861, 2023. e-Pub 2023. PMID: 37285225.
- Ngo-Huang AT, Parker NH, Xiao L, Schadler KL, Petzel MQB, Prakash LR, Kim MP, Tzeng CD, Lee JE, Ikoma N, Wolff RA, Javle MM, Koay EJ, Pant SD, Folloder JP, Wang X, Cotto AM, Ju YR, Garg N, Wang H, Bruera ED, Basen-Engquist KM, Katz MHG. Effects of a Pragmatic Home-based Exercise Program Concurrent with Neoadjuvant Therapy on Physical Function of Patients with Pancreatic Cancer: The Pancfit Randomized Clinical Trial. Ann Surg 278(1):22-30, 2023. e-Pub 2023. PMID: 37026453.
- Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD. Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 21(7):753-782, 2023. e-Pub 2023. PMID: 37433437.
- Liang TZ, Katz MHG, Prakash LR, Chatterjee D, Wang H, Kim M, Tzeng CD, Ikoma N, Wolff RA, Zhao D, Koay EJ, Maitra A, Kundu S, Wang H. Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreatoduodenectomy. Cancers (Basel) 15(12), 2023. e-Pub 2023. PMID: 37370842.
- Tong YT, Lai Z, Katz MHG, Prakash LR, Wang H, Chatterjee D, Kim M, Tzeng CD, Lee JE, Ikoma N, Rashid A, Wolff RA, Zhao D, Koay EJ, Maitra A, Wang H. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. Cancers (Basel) 15(9), 2023. e-Pub 2023. PMID: 37174073.
- Sohn AJ, Taherian M, Katz MHG, Prakash LR, Chatterjee D, Wang H, Kim M, Tzeng CD, Lee JE, Ikoma N, Rashid A, Wolff RA, Zhao D, Koay EJ, Sun R, Maitra A, Wang H. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Am J Surg Pathol 47(4):421-430, 2023. e-Pub 2023. PMID: 36746143.
- Newhook TE, Vreeland TJ, Griffin JF, Tidwell RSS, Prakash LR, Koay EJ, Ludmir EB, Smaglo BG, Pant S, Overman M, Wolff RA, Ikoma N, Maxwell J, Kim MP, Lee JE, Katz MHG, Tzeng CD. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Ann Surg 277(3):484-490, 2023. e-Pub 2023. PMID: 36649067.
- Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol 7(1):16, 2023. e-Pub 2023. PMID: 36781990.
- Kang Y, Deng J, Ling J, Li X, Chiang YJ, Koay EJ, Wang H, Burks JK, Chiao PJ, Hurd MW, Bhutani MS, Lee JH, Weston BR, Maitra A, Ikoma N, Tzeng CD, Lee JE, DePinho RA, Wolff RA, Pant S, McAllister F, Katz MH, Fleming JB, Kim MP. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. J Clin Invest 132(24), 2022. e-Pub 2022. PMID: 36282600.
- Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget 13(1):1314-1321, 2022. e-Pub 2022. PMID: 36473155.
- Serpas Higbie V, Rogers J, Hwang H, Qiao W, Xiao L, Dasari A, Mola-Rudd K, Morris VK, Wolff RA, Raghav K, Huey R, Parseghian C, Willis J, Kopetz S, Overman MJ, Johnson B. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist 27(11):952-957, 2022. e-Pub 2022. PMID: 35946836.
- Koay EJ, Zaid M, Aliru M, Bagereka P, Van Wieren A, Rodriguez MJ, Jacobson G, Wolff RA, Overman M, Varadhachary G, Pant S, Wang H, Tzeng CW, Ikoma N, Kim M, Lee JE, Katz MH, Tamm E, Bhosale P, Taniguchi CM, Holliday EB, Smith GL, Ludmir EB, Minsky BD, Crane CH, Koong AC, Das P, Wang X, Javle M, Krishnan S. Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients with Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase I Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys 114(3):444-453, 2022. e-Pub 2022. PMID: 35863672.
- Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open 5(10):e2236357, 2022. e-Pub 2022. PMID: 36239938.
- Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
- Wang CX, Elganainy D, Zaid MM, Butner JD, Agrawal A, Nizzero S, Minsky BD, Holliday EB, Taniguchi CM, Smith GL, Koong AC, Herman JM, Das P, Maitra A, Wang H, Wolff RA, Katz MHG, Crane CH, Cristini V, Koay EJ. Mass transport model of radiation response: calibration and application to chemoradiation for pancreatic cancer. Int J Radiat Oncol Biol Phys 114(1):163-172, 2022. e-Pub 2022. PMID: 35643254.
- Hester, CA, Perri, G, Prakash, L, Maxwell, JE, Ikoma, N, Kim, M, Tzeng, CD, Smaglo, BG, Wolff, RA, Javle, M, Overman, MJ, Lee, JE, Katz, MH. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. JNCCN Journal of the National Comprehensive Cancer Network 20(8):887-897, 2022. e-Pub 2022. PMID: 35948035.
- Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer 10(8), 2022. e-Pub 2022. PMID: 36007963.
- Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O'Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med 28(6):1167-1177, 2022. e-Pub 2022. PMID: 35662283.
- Lee S, Shroff RT, Makawita S, Xiao L, Danner De Armas A, Bhosale P, Reddy K, Shalaby A, Raghav K, Pant S, Wolff RA, Javle M. Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated by Gemcitabine-based Chemotherapy. Clin Cancer Res 28(11):2229-2236, 2022. e-Pub 2022. PMID: 35312753.
- Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol 13(2):647-656, 2022. e-Pub 2022. PMID: 35557581.
- Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 7(3):208-218, 2022. e-Pub 2022. PMID: 35065057.
- Morris, VK, Overman, MJ, Lam, MC, Parseghian, C, Johnson, B, Dasari, NV, Raghav, KS, Kee, BK, Huey, RW, Wolff, RA, Shen, JY, Li, J, Zorrilla, I, Tzeng, CD, Tran Cao, HS, Chun, YS, Newhook, TE, Vauthey, JN, Duose, D, Luthra, R, Haymaker, CL, Kopetz, S. Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer. Cancer Research Communications 2(9):979-986, 2022. e-Pub 2022.
- Douglas JE, Liu S, Ma J, Wolff RA, Pant S, Maitra A, Tamm EP, Bhosale P, Katz MHG, Varadhachary GR, Koay EJ. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. BMC Cancer 22(1):14, 2022. e-Pub 2022. PMID: 34980020.
- Kaseb AO, Haque A, Vishwamitra D, Hassan MM, Xiao L, George B, Sahu V, Mohamed YI, Carmagnani Pestana R, Lombardo JL, Avritscher R, Yao JC, Wolff RA, Rashid A, Morris JS, Amin HM. Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma. Front Oncol 12:986305, 2022. e-Pub 2022. PMID: 36276070.
- Haque A, Sahu V, Lombardo JL, Xiao L, George B, Wolff RA, Morris JS, Rashid A, Kopchick JJ, Kaseb AO, Amin HM. Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. J Hepatocell Carcinoma 9:823-837, 2022. e-Pub 2022. PMID: 35996397.
- Tong YT, Wang H, Wei D, Prakash LR, Kim M, Tzeng CD, Lee JE, Rashid A, Koay EJ, Wolff RA, Maitra A, Katz MH, Wang H. GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first. Pancreatology 21(7):1378-1385, 2021. e-Pub 2021. PMID: 34429247.
- Zhao J, Soto LMS, Wang H, Katz MH, Prakash LR, Kim M, Tzeng CD, Lee JE, Wolff RA, Huang Y, Wistuba II, Maitra A, Wang H. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Pancreatology 21(5):942-949, 2021. e-Pub 2021. PMID: 33832821.
- Mohindroo C, Hasanov M, Rogers JE, Dong W, Prakash LR, Baydogan S, Mizrahi JD, Overman MJ, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Lotze MT, Kim MP, Katz MHG, Pant S, Tzeng CD, McAllister F. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med 10(15):5041-5050, 2021. e-Pub 2021. PMID: 34250759.
- Morris JS, Hassan MM, Zohner YE, Wang Z, Xiao L, Rashid A, Haque A, Abdel-Wahab R, Mohamed YI, Ballard KL, Wolff RA, George B, Li L, Allen G, Weylandt M, Li D, Wang W, Raghav K, Yao J, Amin HM, Kaseb AO. HepatoScore-14: Measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk. Hepatology 73(6):2278-2292, 2021. e-Pub 2021. PMID: 32931023.
- Bhamidipati D, Colina A, Hwang H, Wang H, Katz M, Fournier K, Serpas V, Thomas J, Sun R, Wolff RA, Raghav K, Overman MJ. Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy. ESMO Open 6(3):100132, 2021. e-Pub 2021. PMID: 33940348.
- Javle M, Shacham-Shmueli E, Xiao L, Varadhachary G, Halpern N, Fogelman D, Boursi B, Uruba S, Margalit O, Wolff RA, Golan T. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. JAMA Oncol 7(5):693-699, 2021. e-Pub 2021. PMID: 33662100.
- Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(4):439-457, 2021. e-Pub 2021. PMID: 33845462.
- Mohamed YI, Lee S, Xiao L, Hassan MM, Qayyum A, Hiatia R, Pestana RC, Haque A, George B, Rashid A, Duda DG, Elghazaly H, Wolff RA, Morris JS, Yao J, Amin HM, Kaseb AO. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget 12(8):756-766, 2021. e-Pub 2021. PMID: 33889299.
- O'Hara MH, O'Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Mick R, Gherardini PF, Kitch LJ, Xu J, Samuel T, Karakunnel J, Fairchild J, Bucktrout S, LaVallee TM, Selinsky C, Till JE, Carpenter EL, Alanio C, Byrne KT, Chen RO, Trifan OC, Dugan U, Horak C, Hubbard-Lucey VM, Wherry EJ, Ibrahim R, Vonderheide RH. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol 22(1):118-131, 2021. e-Pub 2021. PMID: 33387490.
- Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34250391.
- Zaid M, Widmann L, Dai A, Sun K, Zhang J, Zhao J, Hurd MW, Varadhachary GR, Wolff RA, Maitra A, Katz MHG, Herman JM, Wang H, Knopp MV, Williams TM, Bhosale P, Tamm EP, Koay EJ. Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study. Cancers (Basel) 12(12), 2020. e-Pub 2020. PMID: 33291471.
- Colina A, Hwang H, Wang H, Katz MHG, Sun R, Lee JE, Thomas J, Tzeng CW, Wolff RA, Raghav K, Overman MJ. Natural history and prognostic factors for localised small bowel adenocarcinoma. ESMO Open 5(6), 2020. e-Pub 2020. PMID: 33188051.
- Wei D, Zaid MM, Katz MH, Prakash LR, Kim M, Tzeng CD, Lee JE, Agrawal A, Rashid A, Wang H, Varadhachary G, Wolff RA, Tamm EP, Bhosale PR, Maitra A, Koay EJ, Wang H. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Pancreatology. e-Pub 2020. PMID: 33221151.
- Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, Pan BF, Lorenzi PL, Hurd M, Mittendorf EA, Peterson CB, Javle M, Bristow C, Kim M, Tuveson DA, Hawke D, Kopetz S, Wolff RA, Hwu P, Maitra A, Roszik J, Yee C, Lizée G. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun 11(1):5332, 2020. e-Pub 2020. PMID: 33087697.
- Abdel-Wahab R, Hassan MM, George B, Carmagnani Pestana R, Xiao L, Lacin S, Yalcin S, Shalaby AS, Al-Shamsi HO, Raghav K, Wolff RA, Yao JC, Girard L, Haque A, Duda DG, Dima S, Popescu I, Elghazaly HA, Vauthey JN, Aloia TA, Tzeng CW, Chun YS, Rashid A, Morris JS, Amin HM, Kaseb AO. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology:1-11. e-Pub 2020. PMID: 33027788.
- Rogers JE, Jácome AAA, Ohinata A, Wolff R, Morris VK, Johnson B, Mehdizadeh A, Rothschild ND, Ahmed SU, Guerra JL, Eng C. Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. Expert Rev Anticancer Ther:1-8. e-Pub 2020. PMID: 32799569.
- Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Fogelman DR, Raghav KPS, Pant S, McAllister F. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med 9(15):5406-5415, 2020. e-Pub 2020. PMID: 32519420.
- Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. e-Pub 2020. PMID: 32667641.
- Jácome AA, Ohinata A, Mahvash A, Overman MJ, Kee B, Fogelman D, Morris VK, Johnson B, Rothschild ND, Wolff RA, Eng C. Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clin Colorectal Cancer. e-Pub 2020. PMID: 32680816.
- Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. Evolution of Cancer Care in Response to the COVID-19 Pandemic. Oncologist. e-Pub 2020. PMID: 32536024.
- Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Meyers BM, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. Oncologist 25(6):e936-e945, 2020. e-Pub 2020. PMID: 32243668.
- Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. In Reply. Oncologist. e-Pub 2020. PMID: 32378772.
- Mizrahi JD, Rogers JE, Hess KR, Wolff RA, Varadhachary GR, Javle MM, Shroff RT, Ho L, Fogelman DR, Raghav KPS, Overman MJ, Pant S. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology 20(3):501-504, 2020. e-Pub 2020. PMID: 31932214.
- Goldstein JB, Zhao L, Wang X, Ghelman Y, Overman MJ, Javle MM, Shroff RT, Varadhachary GR, Wolff RA, McAllister F, Futreal A, Fogelman DR. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clin Cancer Res 26(6):1385-1394, 2020. e-Pub 2020. PMID: 31871297.
- Rogers JE, Mizrahi JD, Shroff RT, Nelson DA, Tu J, Javle MM, Wolff RA, Pant S. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. J Gastrointest Oncol 11(1):55-60, 2020. e-Pub 2020. PMID: 32175105.
- Bhutani MS, Klapman JB, Tuli R, El-Haddad G, Hoffe S, Wong FCL, Chasen B, Fogelman DR, Lo SK, Nissen NN, Hendifar AE, Varadhachary G, Katz MHG, Erwin WD, Koay EJ, Tamm EP, Singh BS, Mehta R, Wolff RA, Soman A, Cazacu IM, Herman JM. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endosc Ultrasound 9(1):24-30, 2020. e-Pub 2020. PMID: 31670288.
- Eng C, Jácome AA, Das P, Chang GJ, Rodriguez-Bigas M, Skibber JM, Wolff RA, Qiao W, Xing Y, Sethi S, Ohinata A, Crane CH. A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. Clin Colorectal Cancer 18(4):301-306, 2019. e-Pub 2019. PMID: 31350201.
- Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC. Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol 26(13):4489-4497, 2019. e-Pub 2019. PMID: 31418130.
- Luo Y, Yang Y, Liu M, Wang D, Wang F, Bi Y, Ji J, Li S, Liu Y, Chen R, Huang H, Wang X, Swidnicka-Siergiejko AK, Janowitz T, Beyaz S, Wang G, Xu S, Bialkowska AB, Luo CK, Pin CL, Liang G, Lu X, Wu M, Shroyer KR, Wolff RA, Plunkett W, Ji B, Li Z, Li E, Li X, Yang VW, Logsdon CD, Abbruzzese JL, Lu W. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. Gastroenterology 157(5):1413-1428.e11, 2019. e-Pub 2019. PMID: 31352001.
- Wang M, Estrella JS, Katz MH, Kim M, Rashid A, Lee JE, Maitra A, Wistuba II, Wolff RA, Varadhachary GR, Wang H. Expression of Epithelial-Mesenchymal Transition Markers in Treated Pancreatic Ductal Adenocarcinoma. Pancreas 48(10):1367-1372, 2019. e-Pub 2019. PMID: 31688603.
- Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res 25(20):6107-6118, 2019. e-Pub 2019. PMID: 31363003.
- Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz S. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer 121(6):505-510, 2019. e-Pub 2019. PMID: 31406299.
- Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol 5(6):824-830, 2019. e-Pub 2019. PMID: 30998813.
- Aldrich JD, Raghav KPS, Varadhachary GR, Wolff RA, Overman MJ. Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma. Oncologist 24(6):e384-e386, 2019. e-Pub 2019. PMID: 30598498.
- Bhutani MS, Cazacu IM, Luzuriaga Chavez AA, Singh BS, Wong FCL, Erwin WD, Tamm EP, Mathew GG, Le DB, Koay EJ, Taniguchi CM, Minsky BD, Pant S, Tzeng CD, Koong AC, Varadhachary GR, Katz MHG, Wolff RA, Fogelman DR, Herman JM. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. VideoGIE 4(5):223-225, 2019. e-Pub 2019. PMID: 31065616.
- Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G. Pancreatic Adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw 17(3):202-210, 2019. e-Pub 2019. PMID: 30865919.
- Gulhati P, Prakash L, Katz MHG, Wang X, Javle M, Shroff R, Fogelman D, Lee JE, Tzeng CD, Lee JH, Weston B, Tamm E, Bhosale P, Koay EJ, Maitra A, Wang H, Wolff RA, Varadhachary GR. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 26(2):619-627, 2019. e-Pub 2019. PMID: 30324485.
- Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24(23):5883-5894, 2018. e-Pub 2018. PMID: 30082477.
- Pestana RC, Hassan MM, Abdel-Wahab R, Abugabal YI, Girard LM, Li D, Chang P, Raghav K, Morris J, Wolff RA, Rashid A, Amin HM, Kaseb A. Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget 9(102):37721-37732, 2018. e-Pub 2018. PMID: 30701027.
- Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol. e-Pub 2018. PMID: 29982323.
- Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, Overman MJ, Wolff RA, Javle M. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol 11(1):71, 2018. e-Pub 2018. PMID: 29843755.
- Amer AM, Zaid M, Chaudhury B, Elganainy D, Lee Y, Wilke CT, Cloyd J, Wang H, Maitra A, Wolff RA, Varadhachary G, Overman MJ, Lee JE, Fleming JB, Tzeng CW, Katz MH, Holliday EB, Krishnan S, Minsky BD, Herman JM, Taniguchi CM, Das P, Crane CH, Le O, Bhosale P, Tamm EP, Koay EJ. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer 124(8):1701-1709, 2018. e-Pub 2018. PMID: 29370450.
- Kutlu OC, Lee JE, Katz MH, Tzeng CD, Wolff RA, Varadhachary GR, Vauthey JN, Fleming JB, Conrad C. Open Pancreaticoduodenectomy Case Volume Predicts Outcome of Laparoscopic Approach: A Population-based Analysis. Ann Surg 267(3):552-560, 2018. e-Pub 2018. PMID: 28045744.
- Wolff RA, Wang-Gillam A, Alvarez H, Tiriac H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, Castillo J, Kim D, Mulu F, Huang J, Stephens B, Wistuba II, Katz M, Varadhachary G, Park Y, Hicks J, Chinnaiyan A, Scampavia L, Spicer T, Gerhardinger C, Maitra A, Tuveson D, Rinn J, Lizee G, Yee C, Levine AJ. Dynamic changes during the treatment of pancreatic cancer. Oncotarget 9(19):14764-14790, 2018. e-Pub 2018. PMID: 29599906.
- Voong KR, Rashid A, Crane CH, Minsky BD, Krishnan S, Yao JC, Wolff RA, Skibber JM, Feig BW, Chang GJ, Das P. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal. Am J Clin Oncol 40(6):555-560, 2017. e-Pub 2017. PMID: 26237193.
- Parseghian CM, Raghav K, Wolff RA, Ensor J, Yao J, Ellis LM, Tam AL, Overman MJ. Under-reporting of Research Biopsies from Clinical Trials in Oncology. Clin Cancer Res 23(21):6450-6457, 2017. e-Pub 2017. PMID: 28754815.
- Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg 152(11):1048-1056, 2017. e-Pub 2017. PMID: 28700784.
- Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 15(11):1791-1799, 2017. e-Pub 2017. PMID: 28579181.
- Nejati R, Goldstein JB, Halperin DM, Wang H, Hejazi N, Rashid A, Katz MH, Lee JE, Fleming JB, Rodriguez-Canales J, Blando J, Wistuba II, Maitra A, Wolff RA, Varadhachary GR, Wang H. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Pancreas 46(9):1180-1187, 2017. e-Pub 2017. PMID: 28902789.
- Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget 8(50):87163-87173, 2017. e-Pub 2017. PMID: 29152071.
- Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(8):1028-1061, 2017. e-Pub 2017. PMID: 28784865.
- Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 23(15):4146-4154, 2017. e-Pub 2017. PMID: 28280091.
- Chatterjee D, Katz MH, Foo WC, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, Rashid A, Wang H. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy. Am J Surg Pathol 41(8):1097-1104, 2017. e-Pub 2017. PMID: 28614206.
- Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol 35(23):JCO2016714394, 2017. e-Pub 2017. PMID: 28486044.
- Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey JN, Fleming JB, Lee JE, Katz MHG. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol 24(7):2031-2039, 2017. e-Pub 2017. PMID: 28124275.
- Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. e-Pub 2017. PMID: 28424412.
- Park IJ, You YN, Skibber JM, Rodriguez-Bigas MA, Das P, Eng C, Kopetz S, Wolff RA, Crane CH, Krishnan S, Minsky B, Hu CY, Nguyen S, Chang GJ. Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol 40(3):277-282, 2017. e-Pub 2017. PMID: 27028350.
- Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer 123(6):1011-1017, 2017. e-Pub 2017. PMID: 27859010.
- Uemura M, Qiao W, Fournier K, Morris J, Mansfield P, Eng C, Royal RE, Wolff RA, Raghav K, Mann GN, Overman MJ. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer 17(1):331, 2017. e-Pub 2017. PMID: 28506255.
- Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446-453, 2017. e-Pub 2017. PMID: 28223062.
- Chadha AS, Liu G, Chen HC, Das P, Minsky BD, Mahmood U, Delclos ME, Suh Y, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary GR, Wolff RA, Crane CH, Wang X, Thames H, Krishnan S. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?. Int J Radiat Oncol Biol Phys 97(2):323-332, 2017. e-Pub 2017. PMID: 28068240.
- Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg 21(1):164-174, 2017. e-Pub 2017. PMID: 27778257.
- Liu Q, Stewart J, Wang H, Rashid A, Zhao J, Katz MH, Lee JE, Fleming JB, Maitra A, Wolff RA, Varadhachary GR, Krishnan S, Wang H. Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma. PLoS One 12(2):e0171985, 2017. e-Pub 2017. PMID: 28187218.
- Sarshekeh AM, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(3):e0173345, 2017. e-Pub 2017. PMID: 28267766.
- Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One 12(8):e0183949, 2017. e-Pub 2017. PMID: 28850629.
- Lee SM, Katz MH, Liu L, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, Rashid A, Wang H. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival. Am J Surg Pathol 40(12):1653-1660, 2016. e-Pub 2016. PMID: 27631521.
- Al-Shamsi HO, Jones J, Fahmawi Y, Dahbour I, Tabash A, Abdel-Wahab R, Abousamra AO, Shaw KR, Xiao L, Hassan MM, Kipp BR, Kopetz S, Soliman AS, McWilliams RR, Wolff RA. Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. J Gastrointest Oncol 7(6):882-902, 2016. e-Pub 2016. PMID: 28078112.
- Colbert LE, Moningi S, Chadha AS, Wolff RA, Varadhachary GR, Fleming JB, Katz M, Taniguchi CM, Das P, Krishnan S, Koay EJ, Crane CH. Dose Escalation With an Intensity Modulated Radiation Therapy Technique in 15 to 28 Fractions Is Better Tolerated Than Are Standard Doses of 3DCRT for LAPC. Int J Radiat Oncol Biol Phys 96(2S):E151-E152, 2016. e-Pub 2016. PMID: 27673913.
- de Geus SW, Evans DB, Bliss LA, Eskander MF, Smith JK, Wolff RA, Miksad RA, Weinstein MC, Tseng JF. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. Eur J Surg Oncol 42(10):1552-60, 2016. e-Pub 2016. PMID: 27570116.
- Kaseb AO, Hassan M, Lacin S, Abdel-Wahab R, Amin HM, Shalaby A, Wolff RA, Yao J, Rashid A, Vennapusa B, Feng J, Ohtomo T. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. e-Pub 2016. PMID: 27655712.
- Cloyd JM, Crane CH, Koay EJ, Das P, Krishnan S, Prakash L, Snyder RA, Varadhachary GR, Wolff RA, Javle M, Shroff RT, Fogelman D, Overman M, Wang H, Maitra A, Lee JE, Fleming JB, Katz MH. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer 122(17):2671-9, 2016. e-Pub 2016. PMID: 27243381.
- Al-Shamsi HO, Alzahrani M, Wolff RA. The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. J Gastrointest Oncol 7(3):E45-51, 2016. e-Pub 2016. PMID: 27284488.
- Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol 27(6):1068-74, 2016. e-Pub 2016. PMID: 27045102.
- San Lucas FA, Allenson K, Bernard V, Castillo J, Kim DU, Ellis K, Ehli EA, Davies GE, Petersen JL, Li D, Wolff R, Katz M, Varadhachary G, Wistuba I, Maitra A, Alvarez H. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol 27(4):635-41, 2016. e-Pub 2016. PMID: 26681674.
- Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, Minsky BD, Mahmood U, Delclos ME, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary GR, Wolff RA, Crane CH. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int J Radiat Oncol Biol Phys 94(4):755-65, 2016. e-Pub 2016. PMID: 26972648.
- Chouhan J, Gupta R, Ensor J, Raghav K, Fogelman D, Wolff RA, Fisch M, Overman MJ. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Med 5(2):239-47, 2016. e-Pub 2016. PMID: 26714799.
- Ganesan P, Ali SM, Wang K, Blumenschein GR, Esmaeli B, Wolff RA, Miller VA, Stephens PJ, Ross JS, Palmer GA, Janku F. Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. J Clin Oncol 34(5):e34-7, 2016. e-Pub 2016. PMID: 24934779.
- Fischer LK, Katz MH, Lee SM, Liu L, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Roland CL, Fleming JB, Estrella J, Rashid A, Wang H. The Number and Ratio of Positive Lymph Nodes Affect Pancreatic Cancer Patient Survival after Neoadjuvant Therapy and Pancreaticoduodenectomy. Histopathology 68(2):210-20, 2016. e-Pub 2016. PMID: 25945396.
- Overman MJ, Soifer HS, Schueneman AJ, Ensor J, Adsay V, Saka B, Neishaboori N, Wolff RA, Wang H, Schnabel CA, Varadhachary G. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. BMC Cancer 16:668, 2016. e-Pub 2016. PMID: 27549176.
- Chadha AS, Skinner HD, Gunther JR, Munsell MF, Das P, Minsky BD, Delclos ME, Chatterjee D, Wang H, Clemons M, George G, Singh PK, Katz MH, Fleming JB, Javle MM, Wolff RA, Varadhachary GR, Crane CH, Krishnan S. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS One 11(6):e0156910, 2016. e-Pub 2016. PMID: 27336466.
- Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther 9:773-80, 2016. e-Pub 2016. PMID: 26929648.
- Roland CL, Katz MH, Tzeng CW, Lin H, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Vauthey JN, Crane CH, Lee JE, Fleming JB. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol 22 Suppl 3:1221-8, 2015. e-Pub 2015. PMID: 26350371.
- Morris VK, Rashid A, Rodriguez-Bigas M, Das P, Chang G, Ohinata A, Rogers J, Crane C, Wolff RA, Eng C. Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist 20(11):1247-52, 2015. e-Pub 2015. PMID: 26382740.
- Liu L, Katz MH, Lee SM, Fischer LK, Prakash L, Parker N, Wang H, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Maitra A, Fleming JB, Estrella J, Rashid A, Wang H. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Am J Surg Pathol 39(10):1395-403, 2015. e-Pub 2015. PMID: 26200098.
- Xia M, Overman MJ, Rashid A, Chatterjee D, Wang H, Katz MH, Fleming JB, Lee JE, Varadhachary GR, Wolff RA, Wang H. Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol 46(9):1315-22, 2015. e-Pub 2015. PMID: 26165226.
- Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, Fogelman D, Shureiqi I, Jacobs C, Malik Z, Jimenez CA, Wolff RA, Abbruzzese JL, Gallick G, Eng C. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs 33(4):977-84, 2015. e-Pub 2015. PMID: 26062928.
- Abdel-Wahab R, Shehata S, Hassan MM, Xiao L, Lee JS, Cheung S, Essa HH, Hassabo HM, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, Kaseb AO. Validation of an IGF-CTP scoring system for assessing hepatic reserve in egyptian patients with hepatocellular carcinoma. Oncotarget 6(25):21193-207, 2015. e-Pub 2015. PMID: 26098859.
- Choe JH, Overman MJ, Fournier KF, Royal RE, Ohinata A, Rafeeq S, Beaty K, Phillips JK, Wolff RA, Mansfield PF, Eng C. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol 22(8):2578-84, 2015. e-Pub 2015. PMID: 25582740.
- Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology 149(1):119-29, 2015. e-Pub 2015. PMID: 25836985.
- Fogelman D, Sugar EA, Oliver G, Shah N, Klein A, Alewine C, Wang H, Javle M, Shroff R, Wolff RA, Abbruzzese JL, Laheru D, Diaz LA. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol. e-Pub 2015. PMID: 26126726.
- Chadha AS, Kocak-Uzel E, Das P, Minsky BD, Delclos ME, Mahmood U, Guha S, Ahmad M, Varadhachary GR, Javle M, Katz MH, Fleming JB, Wolff RA, Crane CH, Krishnan S. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol 54(7):971-8, 2015. e-Pub 2015. PMID: 25608822.
- Al-Shamsi HO, Kee BK, Tetzlaff MT, Wolff RA. Capecitabine-induced leukocytoclastic vasculitis under neoadjuvant chemotherapy for locally advanced colorectal cancer. J Gastrointest Oncol 6(3):E40-3, 2015. e-Pub 2015. PMID: 26029464.
- Herman JM, Hoffman JP, Thayer SP, Wolff RA. Management of the Primary Tumor and Limited Metastases in Patients With Metastatic Pancreatic Cancer. J Natl Compr Canc Netw 13(5):e29-36, 2015. e-Pub 2015. PMID: 26158133.
- Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, Crane CH, Lee JE, Fleming JB. Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer. Ann Surg Oncol 22(4):1168-75, 2015. e-Pub 2015. PMID: 25352267.
- Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. e-Pub 2015. PMID: 25669829.
- Rios Perez MV, Dai B, Koay EJ, Wolff RA, Fleming JB. Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay. Cureus 7(12):e423, 2015. e-Pub 2015. PMID: 26848412.
- Eid A, Hsieh P, Shah P, Wolff R. Cross-sectional longitudinal study of the academic half-day format in a hematology-oncology fellowship training program. BMC Med Educ 15:139, 2015. e-Pub 2015. PMID: 26302745.
- Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol 8(1):58, 2015. e-Pub 2015. PMID: 26022204.
- Wang H, Estrella JS, Chatterjee D, Katz MH, Rashid A, Wang H, Wolff RA, Varadhachary GR, Lee JE, Pisters PW, Abbruzzese JL, Fleming JB. Hepatobiliary/Pancreas Pathology: SY11-3 PANCREATIC DUCTAL ADENOCARCINOMA: NEOADJUVANT THERAPIES AND PATHOLOGY. Pathology 46 Suppl 2:S25, 2014. e-Pub 2014. PMID: 25188109.
- Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. Pancreatic adenocarcinoma, version 2.2014. J Natl Compr Canc Netw 12(8):1083-93, 2014. e-Pub 2014. PMID: 25099441.
- Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, Crane CH, Wolff RA, Varadhachary GR, Pisters PW, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford) 16(5):430-8, 2014. e-Pub 2014. PMID: 23991810.
- Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS. Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma. J Natl Cancer Inst 106(5), 2014. e-Pub 2014. PMID: 24815863.
- Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43(3):343-9, 2014. e-Pub 2014. PMID: 24622062.
- Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs 32(2):279-86, 2014. e-Pub 2014. PMID: 23756764.
- Tzeng CW, Katz MH, Fleming JB, Lee JE, Pisters PW, Holmes HM, Varadhachary GR, Wolff RA, Abbruzzese JL, Vauthey JN, Aloia TA. Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. J Gastrointest Surg 18(1):146-56, 2014. e-Pub 2014. PMID: 24129825.
- Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB, Katz MH. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg 18(1):16-25, 2014. e-Pub 2014. PMID: 24241967.
- Said R, Banchs J, Wheler J, Hess KR, Falchook G, Fu S, Naing A, Hong D, Piha-Paul S, Ye Y, Yeh E, Wolff RA, Tsimberidou AM. The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol 25(1):276-82, 2014. e-Pub 2014. PMID: 24356639.
- Koay EJ, Baio FE, Ondari A, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Zhang J, Court L, Bhosale PR, Tamm EP, Qayyum A, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Maitra A, Ferrari M, Varadhachary GR, Fleming JB. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol 11(6):065002, 2014. e-Pub 2014. PMID: 25427073.
- Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations. Mol Cancer Ther 12(12):2857-63, 2013. e-Pub 2013. PMID: 24092809.
- Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary GR, Abbruzzese JL, Wolff RA, Lee JE, Evans DB, Fleming JB. The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma. Ann Surg Oncol 20 Suppl 3:500-8, 2013. e-Pub 2013. PMID: 23397153.
- Chatterjee D, Katz MH, Rashid A, Estrella JS, Wang H, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Abbruzzese JL, Fleming JB, Wang H. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. Histopathology 63(6):841-51, 2013. e-Pub 2013. PMID: 24111684.
- Eng C, Chang GJ, You YN, Das P, Xing Y, Delclos M, Wolff RA, Rodriguez-Bigas MA, Skibber J, Ohinata A, Gould S, Phillips J, Crane CH. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer 119(21):3769-75, 2013. e-Pub 2013. PMID: 24037775.
- Shroff S, Overman MJ, Rashid A, Shroff RT, Wang H, Chatterjee D, Katz MH, Lee JE, Wolff RA, Abbruzzese JL, Fleming JB, Wang H. The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. Arch Pathol Lab Med 137(11):1619-26, 2013. e-Pub 2013. PMID: 24168499.
- Khalil MA, Qiao W, Carlson P, George B, Javle M, Overman M, Varadhachary G, Wolff RA, Abbruzzese JL, Fogelman DR. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs 31(5):1375-83, 2013. e-Pub 2013. PMID: 23645398.
- Jiang ZQ, Varadhachary G, Wang X, Kopetz S, Lee JE, Wang H, Shroff R, Katz M, Wolff RA, Fleming J, Overman MJ. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol 24(9):2349-53, 2013. e-Pub 2013. PMID: 23704197.
- Tzeng CW, Abbott DE, Cantor SB, Fleming JB, Lee JE, Pisters PW, Varadhachary GR, Abbruzzese JL, Wolff RA, Ahmad SA, Katz MH. Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis. Ann Surg Oncol 20(7):2197-203, 2013. e-Pub 2013. PMID: 23408126.
- Wang W, Shpaner A, Krishna SG, Ross WA, Bhutani MS, Tamm EP, Raju GS, Xiao L, Wolff RA, Fleming JB, Lee JH. Use of EUS-FNA in diagnosing pancreatic neoplasm without a definitive mass on CT. Gastrointest Endosc 78(1):73-80, 2013. e-Pub 2013. PMID: 23523302.
- Foo WC, Rashid A, Wang H, Katz MH, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, Fleming JB, Wang H. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol 44(6):1024-30, 2013. e-Pub 2013. PMID: 23260327.
- Tsimberidou AM, Ye Y, Wheler J, Naing A, Hong D, Nwosu U, Hess KR, Wolff RA. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol 71(4):955-63, 2013. e-Pub 2013. PMID: 23377373.
- Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 4(1):153-62, 2013. e-Pub 2013. PMID: 23847722.
- Raghav KP, Shetty AV, Kazmi SM, Zhang N, Morris J, Taggart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff RA, Overman MJ. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist 18(12):1270-7, 2013. e-Pub 2013. PMID: 24149137.
- Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, Charnsangavej C, Tamm E, Crane CH, Balachandran A. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118(23):5749-56, 2012. e-Pub 2012. PMID: 22605518.
- Roland CL, Katz MH, Gonzalez GM, Pisters PW, Vauthey JN, Wolff RA, Crane CH, Lee JE, Fleming JB. A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma. J Gastrointest Surg 16(11):2056-63, 2012. e-Pub 2012. PMID: 22914983.
- Wolff RA. Pancreatic cancer: Is it time for Dr Whipple's orphans to have a Facebook page?. Nat Rev Clin Oncol 9(10):553-4, 2012. e-Pub 2012. PMID: 22965153.
- Thomas RM, Truty MJ, Nogueras-Gonzalez GM, Fleming JB, Vauthey JN, Pisters PW, Lee JE, Rice DC, Hofstetter WL, Wolff RA, Varadhachary GR, Wang H, Katz MH. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg 16(9):1696-704, 2012. e-Pub 2012. PMID: 22644446.
- Wolff RA, Fuchs M, Di Bartolomeo M, Hossain AM, Stoffregen C, Nicol S, Heinemann V. A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. Cancer 118(17):4132-8, 2012. e-Pub 2012. PMID: 22213153.
- Truty MJ, Thomas RM, Katz MH, Vauthey JN, Crane C, Varadhachary GR, Wolff RA, Abbruzzese JL, Lee JE, Fleming JB. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg 215(1):41-51; discussion 51-2, 2012. e-Pub 2012. PMID: 22608401.
- Tzeng CW, Fleming JB, Lee JE, Wang X, Pisters PW, Vauthey JN, Varadhachary G, Wolff RA, Katz MH. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford) 14(6):365-72, 2012. e-Pub 2012. PMID: 22568412.
- Wolff RA. Neoadjuvant therapy for resectable and borderline resectable adenocarcinoma of the pancreas. Curr Drug Targets 13(6):781-8, 2012. e-Pub 2012. PMID: 22458524.
- Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, Lee JE, Pisters PW, Vauthey JN, Crane C, Gomez HF, Abbruzzese JL, Fleming JB, Wang H. Histologic grading the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: A predictor for patient outcome. Cancer 118(12):3182-90, 2012. e-Pub 2012. PMID: 22028089.
- Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Fogelman DR, Crane CH, Balachandran A, Katz MH. Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy. Ann Surg Oncol 19(6):2045-53, 2012. e-Pub 2012. PMID: 22258816.
- Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA, Cancer Networks NC. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 10(6):703-13, 2012. e-Pub 2012. PMID: 22679115.
- Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J. PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors. Clin Cancer Res 18(6):1777-89, 2012. e-Pub 2012. PMID: 22422409.
- Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S, Rafeeq S, Taggart M, Fournier K, Royal R, Mansfield P, Overman MJ. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol 23(3):652-8, 2012. e-Pub 2012. PMID: 21653683.
- Chatterjee D, Katz MH, Rashid A, Wang H, Iuga AC, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Crane CH, Gomez HF, Abbruzzese JL, Fleming JB, Wang H. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol 36(3):409-17, 2012. e-Pub 2012. PMID: 22301497.
- Overman MJ, Hu CY, Kopetz S, Abbruzzese JL, Wolff RA, Chang GJ. A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease. Ann Surg Oncol. e-Pub 2011. PMID: 22187121.
- Fogelman D, Jafari M, Varadhachary GR, Xiong H, Bullock S, Ozer H, Lin E, Morris J, Cunningham P, Bennett B, Abbruzzese JL, Wolff RA. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 68(6):1431-8, 2011. e-Pub 2011. PMID: 21479635.
- Carmack CL, Basen-Engquist K, Yuan Y, Greisinger A, Rodriguez-Bigas M, Wolff RA, Barker T, Baum G, Pennebaker JW. Feasibility of an expressive-disclosure group intervention for post-treatment colorectal cancer patients: Results of the healthy expressions study. Cancer 117(21):4993-5002, 2011. e-Pub 2011. PMID: 21480203.
- Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29(22):3037-43, 2011. e-Pub 2011. PMID: 21709185.
- Dakik HK, Moskovic DJ, Carlson PJ, Tamm EP, Qiao W, Wolff RA, Abbruzzese JL, Fogelman DR. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. e-Pub 2011. PMID: 21850466.
- El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs 29(4):694-9, 2011. e-Pub 2011. PMID: 20107864.
- Evans DB, Wolff RA. Adjuvant therapy for pancreatic cancer: a logical strategy in search of progress. Ann Surg Oncol 18(5):1224-8, 2011. e-Pub 2011. PMID: 21384245.
- Hecht JR, Trarbach T, Hainsworth JD, Major P, Jäger E, Wolff RA, Lloyd-Salvant K, Bodoky G, Pendergrass K, Berg W, Chen BL, Jalava T, Meinhardt G, Laurent D, Lebwohl D, Kerr D. Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma. J Clin Oncol 29(15):1997-2003, 2011. e-Pub 2011. PMID: 21464406.
- Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 31(4):1417-20, 2011. e-Pub 2011. PMID: 21508395.
- Tamm EP, Loyer EM, Faria S, Raut CP, Evans DB, Wolff RA, Crane CH, Dubrow RA, Charnsangavej C. Erratum to: Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging. e-Pub 2011. PMID: 21350817.
- Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R. Phase 1 clinical trials in 83 patients with pancreatic cancer: the M. D. Anderson Cancer Center experience. Cancer 117(1):77-85, 2011. e-Pub 2011. PMID: 20737567.
- Varadhachary GR, Wolff RA. The war on pancreatic cancer: are we gaining ground?. Oncology (Williston Park) 24(14):1335-6, 2010. e-Pub 2010. PMID: 21294479.
- Overman MJ, Hu CY, Wolff RA, Chang GJ. Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer 116(23):5374-82, 2010. e-Pub 2010. PMID: 20715162.
- Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 8(9):972-1017, 2010. e-Pub 2010. PMID: 20876541.
- Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 49(4):474-9, 2010. e-Pub 2010. PMID: 20397775.
- Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA, Kopetz S. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28(15):2549-55, 2010. e-Pub 2010. PMID: 20406923.
- Crane CH, Varadhachary GR, Wolff RA, Fleming JB. Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy. Ann Surg Oncol 17(4):950-2, 2010. e-Pub 2010. PMID: 20012500.
- Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA. Phase II Trial of Neoadjuvant Bevacizumab, Capecitabine, and Radiotherapy for Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 76(3):824-30, 2010. e-Pub 2010. PMID: 19464823.
- Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H, Crane CH, Lee JH, Tamm EP, Abbruzzese JL, Evans DB. Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation. Ann Surg Oncol. e-Pub 2010. PMID: 20162463.
- Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102(1):144-50, 2010. e-Pub 2010. PMID: 19935793.
- Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. J Clin Oncol 28(3):453-9, 2010. e-Pub 2010. PMID: 20008624.
- Shapiro JF, Chase JL, Wolff RA, Lambert LA, Mansfield PF, Overman MJ, Ohinata A, Liu J, Wang X, Eng C. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer 116(2):316-22, 2010. e-Pub 2010. PMID: 19904805.
- Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, Wolff RA, Willett CG. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 27(25):4096-102, 2009. e-Pub 2009. PMID: 19636002.
- Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C, Wolff RA, Tortorice ML, Tansey P, Gonzalez-Moreno S, Lambert DH, Mansfield PF. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol 16(8):2181-7, 2009. e-Pub 2009. PMID: 19475451.
- Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement. Ann Surg Oncol 16(7):1751-6, 2009. e-Pub 2009. PMID: 19390900.
- Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 27(16):2598-603, 2009. e-Pub 2009. PMID: 19164203.
- Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16(4):836-47, 2009. e-Pub 2009. PMID: 19194760.
- Crane CH, Varadhachary G, Settle SH, Fleming JB, Evans DB, Wolff RA. The integration of chemoradiation in the care of patient with localized pancreatic cancer. Cancer Radiother 13(2):123-43, 2009. e-Pub 2009. PMID: 19167921.
- Haque W, Crane CH, Krishnan S, Delclos ME, Javle M, Garrett CR, Wolff RA, Das P. Reirradiation to the abdomen for gastrointestinal malignancies. Radiat Oncol 4:55, 2009. e-Pub 2009. PMID: 19922641.
- Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases. J Clin Oncol 26(33):5344-5351, 2008. e-Pub 2008. PMID: 18936472.
- Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113(8):2046-52, 2008. e-Pub 2008. PMID: 18756532.
- Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs 26(5):445-54, 2008. e-Pub 2008. PMID: 18528634.
- Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 113(8):2038-45, 2008. e-Pub 2008. PMID: 18759326.
- Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26(8):794-9, 2008. e-Pub 2008. PMID: 18798063.
- Wolff RA, Varadhachary GR, Evans DB. Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol 15(10):2773-86, 2008. e-Pub 2008. PMID: 18612703.
- Hassan MM, Li D, El-Deeb AS, Wolff RA, Bondy ML, Davila M, Abbruzzese JL. Association between hepatitis B virus and pancreatic cancer. J Clin Oncol 26(28):4557-62, 2008. e-Pub 2008. PMID: 18824707.
- Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer 7(5):338-42, 2008. e-Pub 2008. PMID: 18794067.
- Ross WA, Wasan SM, Evans DB, Wolff RA, Trapani LV, Staerkel GA, Prindiville T, Lee JH. Combined EUS with FNA and ERCP for the evaluation of patients with obstructive jaundice from presumed pancreatic malignancy. Gastrointest Endosc 68(3):461-6, 2008. e-Pub 2008. PMID: 18384788.
- Hoff PM, Kopetz S, Thomas MB, Langleben A, Rinaldi D, Anthony L, Wolff RA, Lassere Y, Abbruzzese JL. A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer 99(5):722-6, 2008. e-Pub 2008. PMID: 18728662.
- Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26(26):4311-8, 2008. e-Pub 2008. PMID: 18779618.
- Evans DB, Crane CH, Charnsangavej C, Wolff RA. The added value of multidisciplinary care for patients with pancreatic cancer. Ann Surg Oncol 15(8):2078-80, 2008. e-Pub 2008. PMID: 18546044.
- Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3496-502, 2008. e-Pub 2008. PMID: 18640930.
- Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3487-95, 2008. e-Pub 2008. PMID: 18640929.
- Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14(14):4491-9, 2008. e-Pub 2008. PMID: 18628464.
- Yu TK, Bhosale PR, Crane CH, Iyer RB, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Wolff RA, Janjan NA, Delclos ME, Krishnan S, Das P. Patterns of Locoregional Recurrence After Surgery and Radiotherapy or Chemoradiation for Rectal Cancer. Int J Radiat Oncol Biol Phys 71(4):1175-80, 2008. e-Pub 2008. PMID: 18207667.
- Weston BR, Ross WA, Wolff RA, Evans D, Lee JE, Wang X, Xiao LC, Lee JH. Rate of bilirubin regression after stenting in malignant biliary obstruction for the initiation of chemotherapy: how soon should we repeat endoscopic retrograde cholangiopancreatography?. Cancer 112(11):2417-23, 2008. e-Pub 2008. PMID: 18404695.
- Kauffman CR, Mahvash A, Kopetz S, Wolff RA, Ensor J, Wallace MJ. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. Cancer 112(10):2283-8, 2008. e-Pub 2008. PMID: 18344210.
- Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206(5):833-46; discussion 846-8, 2008. e-Pub 2008. PMID: 18471707.
- Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol 26(12):2000-5, 2008. e-Pub 2008. PMID: 18421052.
- Falchook GS, Wolff RA, Varadhachary GR. Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases. Gynecol Oncol 108(3):515-9, 2008. e-Pub 2008. PMID: 18164378.
- Heaton NS, Wolff RA, Malinowski RL, Hullett DA, Hoch JR. Antisense to Transforming Growth Factor-beta(1) Facilitates the Apoptosis of Macrophages in Rat Vein Grafts. J Vasc Res 45(5):365-374, 2008. e-Pub 2008. PMID: 18354256.
- Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, Wolff RA, Crane CH, Pisters PW. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys 70(3):735-43, 2008. e-Pub 2008. PMID: 17980502.
- Jiao L, Hassan MM, Bondy ML, Wolff RA, Evans DB, Abbruzzese JL, Li D. XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer. Am J Gastroenterol 103(2):360-7, 2008. e-Pub 2008. PMID: 17986315.
- Politano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz S. Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer 7(1):55-9, 2008. e-Pub 2008. PMID: 18279578.
- Hassan MM, Bondy ML, Wolff RA, Abbruzzese JL, Vauthey JN, Pisters PW, Evans DB, Khan R, Chou TH, Lenzi R, Jiao L, Li D. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 102(12):2696-707, 2007. e-Pub 2007. PMID: 17764494.
- Reyes-Gibby CC, Chan W, Abbruzzese JL, Xiong HQ, Ho L, Evans DB, Varadhachary G, Bhat S, Wolff RA, Crane C. Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. J Pain Symptom Manage 34(3):244-52, 2007. e-Pub 2007. PMID: 17513082.
- Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246(1):52-60, 2007. e-Pub 2007. PMID: 17592291.
- Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans DB, Wolff RA, Crane CH. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 110(1):47-55, 2007. e-Pub 2007. PMID: 17538975.
- Hassan MM, Abbruzzese JL, Bondy ML, Wolff RA, Vauthey JN, Pisters PW, Evans DB, Khan R, Lenzi R, Jiao L, Li D. Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study. Cancer 109(12):2547-56, 2007. e-Pub 2007. PMID: 17492688.
- Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960-6, 2007. e-Pub 2007. PMID: 17452677.
- Tamm EP, Loyer EM, Faria SC, Evans DB, Wolff RA, Charnsangavej C. Retrospective analysis of dual-phase MDCT and follow-up EUS/EUS-FNA in the diagnosis of pancreatic cancer. Abdom Imaging, 2007. e-Pub 2007. PMID: 17522753.
- Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA, Crane CH. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 109(9):1750-5, 2007. e-Pub 2007. PMID: 17387743.
- Li D, Li Y, Jiao L, Chang DZ, Beinart G, Wolff RA, Evans DB, Hassan MM, Abbruzzese JL. Effects of base excision repair gene polymorphisms on pancreatic cancer survival. Int J Cancer 120(8):1748-54, 2007. e-Pub 2007. PMID: 17230526.
- Aloia TE, Lee JE, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Abbruzzese JL, Crane CH, Evans DB, Pisters PW. Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy?. J Am Coll Surg 204(3):347-55, 2007. e-Pub 2007. PMID: 17324767.
- Bedi M, Das P, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Eng C, Wolff RA, Janjan NA, Drishnan S, Crane CH. Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. Gastrointestinal Cancer Research 1:44-48, 2007. e-Pub 2007.
- Das P, Lin EH, Bhatia S, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Delclos ME, Krishnan S, Janjan NA, Crane CH. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 66(5):1378-83, 2006. e-Pub 2006. PMID: 17056196.
- Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, Delclos ME, Palla S, Guha S, Varadhachary G, Evans DB, Wolff RA, Crane CH. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 107(11):2589-96, 2006. e-Pub 2006. PMID: 17083124.
- Wolff RA. Current controversies in the management of pancreatic cancer. Clin Adv Hematol Oncol 4(12):889-91, 2006. e-Pub 2006. PMID: 17235271.
- Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, Delclos ME, Chang GJ, Hoff PM, Eng C, Brown TD, Crane CH, Feig BW, Morris J, Vadhan-Raj S, Hamilton SR, Lin EH. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 66(3):762-71, 2006. e-Pub 2006. PMID: 17011451.
- Whitehead RP, McCoy S, Rivkin SE, Gross HM, Conrad ME, Doolittle GC, Wolff RA, Goodwin JW, Dakhil SR, Abbruzzese JL. A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 24(6):515-20, 2006. e-Pub 2006. PMID: 16699973.
- Tamm EP, Loyer EM, Faria S, Raut CP, Evans DB, Wolff RA, Crane CH, Dubrow RA, Charnsangavej C. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging 31:568-74, 2006. e-Pub 2006. PMID: 16967235.
- Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Janjan NA, Delclos ME, Krishnan S, Levy LB, Ellis LM, Crane CH. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol 29(3):219-24, 2006. e-Pub 2006. PMID: 16755173.
- Hoff PM, Wolff RA, Xiong H, Jones D, Lin E, Eng C, Dutta A, Bogaard KR, Abbruzzese JL. Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer. Cancer 106(10):2241-6, 2006. e-Pub 2006. PMID: 16598762.
- Crane CH, Varadhachary G, Wolff RA, Pisters PW, Evans DB. The Argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Best Pract Res Clin Gastroenterol 20(2):365-382, 2006. e-Pub 2006. PMID: 16549333.
- Raut CP, Cleary KR, Staerkel GA, Abbruzzese JL, Wolff RA, Lee JH, Vauthey JN, Lee JE, Pisters PW, Evans DB. Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol 13(4):582-94, 2006. e-Pub 2006. PMID: 16523362.
- Li D, Liu H, Jiao L, Chang DZ, Beinart G, Wolff RA, Evans DB, Hassan MM, Abbruzzese JL. Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. Cancer Res 66(6):3323-30, 2006. e-Pub 2006. PMID: 16540687.
- Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24(7):1145-1151, 2006. e-Pub 2006. PMID: 16505434.
- Hoff PM, Wolff RA, Bogaard K, Waldrum S, Abbruzzese JL. A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. Jpn J Clin Oncol 36(2):100-3, 2006. e-Pub 2006. PMID: 16449240.
- Li D, Jiao L, Li Y, Doll MA, Hein DW, Bondy ML, Evans DB, Wolff RA, Lenzi R, Pisters PW, Abbruzzese JL, Hassan MM. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 27(1):103-11, 2006. e-Pub 2006. PMID: 15987714.
- Jiao L, Bondy ML, Hassan MM, Wolff RA, Evans DB, Abbruzzese JL, Li D. Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. Cancer Detect Prev 30(3):284-91, 2006. e-Pub 2006. PMID: 16844323.
- Das P, Wolff RA, Abbruzzese JL, Varadhachary GR, Evans DB, Vauthey JN, Baschnagel A, Delclos ME, Krishnan S, Janjan NA, Crane CH. Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol 1:41, 2006. e-Pub 2006. PMID: 17062148.
- Mullen JT, Lee JH, Gomez HF, Ross WA, Fukami N, et al WR. Pancreaticoduodenectomy after Placement of Endobiliary Metal Stents. Journal of Gastrointestinal Surgery 9(8):1094-1104, 2005. e-Pub 2005.
- Varadhachary GR, Tamm EP, Crane C, Evans DB, Wolff RA. Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol 8(5):377-84, 2005. e-Pub 2005. PMID: 16162303.
- Kindler HL, Tothy PK, Wolff RA, McCormack RA, Abbruzzese JL, Mani S, Wade-Oliver KT, Vokes EE. Phase II Trials of Dolastatin-10 in Advanced Pancreaticobiliary Cancers. Invest New Drugs 23(5):489-93, 2005. e-Pub 2005.
- Xiong HQ, Plunkett W, Wolff R, Du M, Lenzi R, Abbruzzese JL. A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 55(6):559-64, 2005. e-Pub 2005. PMID: 15726370.
- Xiong HQ, Wolff RA, Gravel D, Abbruzzese JL. Response to gemcitabine plus cetuximab in a patient with metastatic pancreatic cancer entered on a phase II clinical trial. American Journal of Oncology Review 4(1):35-40, 2005. e-Pub 2005.
- Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22(23):4762-71, 2004. e-Pub 2004. PMID: 15570077.
- Hoff PM, Saad ED, Pazdur R, Wolff R, Lassere Y, Bogaard KR, Abbruzzese JL. Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. Invest New Drugs 22(3):307-13, 2004. e-Pub 2004. PMID: 15122078.
- Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer, II, Wolff RA, Charnsangavej C, Brown TD. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101(3):578-86, 2004. e-Pub 2004. PMID: 15274071.
- Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 22(13):2610-6, 2004. e-Pub 2004. PMID: 15226328.
- Curley SA, Marra P, Beaty K, Ellis LM, Vauthey JN, Abdalla EK, Scaife C, Raut C, Wolff R, Choi H, Loyer E, Vallone P, Fiore F, Scordino F, De Rosa V, Orlando R, Pignata S, Daniele B, Izzo F. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 239(4):450-8, 2004. e-Pub 2004. PMID: 15024305.
- Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, Hesketh P, Rathore R, Wolff R, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Investigation 22(5):706-12, 2004. e-Pub 2004.
- Wolff RA. Are patients with cancer receiving adequate thromboprophylaxis? Results from FRONTLINE. Cancer Treat Rev 29 Suppl 2:7-9, 2003. e-Pub 2003. PMID: 12887943.
- Papagikos M, Crane CH, Skibber J, Janjan NA, Wolff RA, et al. Chemoradiation for adenocarcinoma of the anus. International Journal of Radiation Oncology, Biology & Physics 55(3):669-78, 2003. e-Pub 2003.
- Crane CH, Skibber JM, Feig BW, Vauthey JN, Thames HD, Curley SA, Rodriguez-Bigas MA, Wolff RA, Ellis LM, Delclos ME, Lin EH, Janjan NA. Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 97(2):517-24, 2003. e-Pub 2003. PMID: 12518377.
- Kakkar AK, Levine M, Pinedo, Wolff R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 8(4):381-8, 2003. e-Pub 2003.
- Raut CP, Grau AM, Staerkel GA, Kaw M, Tamm EP, Wolff RA, Vauthey JN, Lee JE, Pisters PW, Evans DB. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg 7(1):118-26; discussion 127-8, 2003. e-Pub 2003. PMID: 12559193.
- Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, Lenzi R, Vauthey JN, Lee JE, Abbruzzese JL, Evans DB. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 20(10):2537-44, 2002. e-Pub 2002. PMID: 12011133.
- Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q, Janjan NA. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?. Int J Radiat Oncol Biol Phys 52(5):1293-302, 2002. e-Pub 2002. PMID: 11955742.
- Wayne JD, Abdalla EK, Wolff RA, Crane CH, Pisters PW, Evans DB. Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist 7(1):34-45, 2002. e-Pub 2002. PMID: 11854545.
- Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, Gagel RF, Ajani JA, Wolff RA, Evans DB. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130(6):1078-85, 2001. e-Pub 2001. PMID: 11742342.
- Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PW, Lee JE, Janjan NA, Charnsangavej C, Abbruzzese JL. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7(8):2246-53, 2001. e-Pub 2001. PMID: 11489798.
- Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey JN, Lynch P, Ellis LM, Wolff R, Lenzi R, Abbruzzese J, Pazdur R, Hoff PM, Allen P, Brown T, Skibber J. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 24(2):107-12, 2001. e-Pub 2001. PMID: 11319280.
- Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8(2):123-32, 2001. e-Pub 2001. PMID: 11258776.
- Crane CH, Janjan NA, Abbruzzese JL, Curley S, Vauthey J, Sawaf HB, Dubrow R, Allen P, Ellis LM, Hoff P, |Wolff RA, Lenzi R, Brown TD, Lynch P, Cleary K, Rich TA, Skibber J. Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. Int J Radiat Oncol Biol Phys 49(1):107-16, 2001. e-Pub 2001. PMID: 11163503.
- Crane CH, Antolak JA, Rosen, II, Forster KM, Evans DB, Janjan NA, Charnsangavej C, Pisters PW, Lenzi R, Papagikos MA, Wolff RA. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 30(3):123-32, 2001. e-Pub 2001. PMID: 12540024.
- Sanfilippo NJ, Crane CH, Skibber J, Feig B, Abbruzzese JA, Curley S, Vauthey JN, Ellis LM, Hoff P, Wolff RA, etal. T4 Rectal Cancer Treated with Preoperative Chemoradiation to the Posterior Pelvis Followed by Multivisceral Resection: Patterns of Failure and Limitations of Treatment. International Journal of Radiation Oncology, Biology, Physics 51(1):176-183, 2001. e-Pub 2001.
- Janjan NA, Crane CN, Feig BW, Cleary K, Dubrow R, Curley SA, Ellis LM, Vauthey J, Lenzi R, Lynch P, Wolff R, Brown T, Pazdur R, Abbruzzese J, Hoff PM, Allen P, Brown B, Skibber J. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 47(3):713-8, 2000. e-Pub 2000. PMID: 10837955.
- Pisters PW, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, Rich TA, Crane CH, Lenzi R, Wolff RA, Abbruzzese JL, Evans DB. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol 18(4):860-7, 2000. e-Pub 2000. PMID: 10673529.
- Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, Allen PK, Lynch PM, Glober G, Wolff R, Rich TA, Skibber J. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 44(5):1027-38, 1999. e-Pub 1999. PMID: 10421535.
- White R, Lee C, Anscher M, Gottfried M, Wolff RA, Keogan M, Pappas T, Hurwitz H, Tyler D. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. Annals of Surgical Oncology 6(1):38-45, 1999. e-Pub 1999.
- Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, Rich TA, Raijman I, Wolff RA, Lenzi R, Lee JE, Evans DB. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 16(12):3843-50, 1998. e-Pub 1998. PMID: 9850029.
- Tepper CG, Jayadev S, Liu B, Bielawska A, Wolff RA, Yonehara YA, Seldin MF. Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America 92(18):8443-7, 1995. e-Pub 1995.
- Dbaibo GS, Wolff RA, Obeid LM, Hannum YA. Activation of a retinoblastoma-protein-dependent pathway by sphingosine. Biochemical Journal 310(Pt 2):453-9, 1995. e-Pub 1995.
- Wolff RA, Dobrowsky RT, Bielawska A, Obeid LM, Hannun YA. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. J Biol Chem 269(30):19605-9, 1994. e-Pub 1994. PMID: 8034729.
- Perreault SD, Wolff RA, Zirkin BR. The Role of Disulfide Bond Reduction During Mammalian Sperm Nuclear Decondensation In Vivo. Dev Biol 101:160-7, 1984. e-Pub 1984.
Invited Articles
- Reyes-Gibby CC, Chan W, Abbruzzese JL, Xiong HQ, Ho L, Evans DB, Varadhachary G, Bhat S, Wolff RA, Crane C. Patterns of Self-Reported Symptoms in Pancreatic Cancer Patients Receiving Chemoradiation. Journal of Pain Symptom Management, 2007. e-Pub 2007.
- Wolff RA. Chemotherapy for pancreatic cancer: from metastatic disease to adjuvant therapy. Cancer Journal 13:175-184, 2007. e-Pub 2007.
- Wolff RA. Current Controversies in the Management of Pancreatic Cancer. Clinical Advances in Hematology & Oncology 4(12):889-891, 2006. e-Pub 2006.
- Tempero MA, Behrman S, Ben-Josef E, Benson AB III, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW II, Melvin WS, Muscarella P II, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA. Pancreatic adenocarcinoma: clinical practice guidelines in oncology. Journal of National Comprehensive Cancer Network 3(5):598-626, 2005. e-Pub 2005.
- Pisters PW, Wolff RA, Crane CH, Evans DB. Combined-modality treatment for operable pancreatic adenocarcinoma. Oncology (Williston Park) 19(3):393-404, 409; discussion 409-10, 412-6, 2005. e-Pub 2005. PMID: 15828554.
- Wolff RA, Vauthey JN. Resection of Liver metastases: State of the Art. Oncology 16(9):1240-1256, 2002. e-Pub 2002.
- Wolff RA. Current Perspectives on Locally Advanced Pancreatic Cancer. Oncology 14(11):1535-1545, 2000. e-Pub 2000.
- Wolff RA. Hepatic Arterial Infusional Therapy for Metastatic Colorectal Cancer. American Society of Clinical Oncology; Clinical Practice Forum Book(Fall):63-68, 2000. e-Pub 2000.
Other Articles
- Bagley AF, Ludmir EB, Maitra A, Minsky BD, Li Smith G, Das P, Koong AC, Holliday EB, Taniguchi CM, Katz MHG, Tamm EP, Wolff RA, Overman MJ, Patel S, Kim MP, Tzeng CD, Ikoma N, Bhutani MS, Koay EJ NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Clin Transl Radiat Oncol 33:66-69, 2022. PMID: 35097226.
- Yavuz BG, Pestana RC, Abugabal YI, Krishnan S, Chen J, Hassan MM, Wolff RA, Rashid A, Amin HM, Kaseb AO Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. Oncotarget 11(13):1186-1201, 2020. PMID: 32284794.
- |Wolff RA Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We?. Surg Clin North Am 98(1):95-111, 2018. PMID: 29191281.
- Varadhachary GR, Wolff RA Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy?. J Oncol Pract 12(9):797-805, 2016. PMID: 27621332.
- Al-Shamsi HO, Alhazzani W, Wolff RA Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. J Gastrointest Oncol 6(3):314-21, 2015. PMID: 26029459.
- Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, Kopetz S Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 8(4):225-30, 2009. PMID: 19822514.
- Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier JN Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19(3):577-82, 2008. PMID: 18024857.
- Crane CH, Varadhachary G, Pisters PW, Evans DB, Wolff RA Future chemoradiation strategies in pancreatic cancer. Semin Oncol 34(4):335-46, 2007. PMID: 17674962.
- Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13(8):1035-46, 2006. PMID: 16865597.
- Li D, Xie K, Wolff R, Abbruzzese JL Pancreatic cancer. Lancet 363(9414):1049-57, 2004. PMID: 15051286.
- Wolff RA Chemoprevention for pancreatic cancer. Int J Gastrointest Cancer 33(1):27-41, 2003. PMID: 12909736.
- Wolff RA Novel therapies for pancreatic cancer. Cancer J 7(4):349-58, 2001. PMID: 11561610.
- Wayne JD, Wolff RA, Pisters PW, Evans DB Multimodality management of localized pancreatic cancer. Cancer J 7 Suppl 1:S35-46, 2001. PMID: 11504284.
- Crane CH, Wolff RA, Abbruzzese JL, Evans DB, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Lahoti S, Vauthey JN, Janjan NA Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol 28(3 Suppl 10):25-33, 2001. PMID: 11510031.
- Evans DB, Wolff RA, Crane CH Neoadjuvant strategies for pancreatic cancer. Oncology (Williston Park) 15(6):727-37; discussion 741-4, 747, 2001. PMID: 11430206.
- Wolff RA, Chiao P, Lenzi R, Pisters PW, Lee JE, Janjan NA, Crane CH, Evans DB, Abbruzzese JL Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs 18(1):43-56, 2000. PMID: 10830140.
- Medgyesy CD, Wolff RA, Putnam JB, Jr, Ajani JA Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson Cancer Center experience and literature review. Cancer 88(2):262-7, 2000. PMID: 10640955.
- Breslin TM, Janjan NA, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, Evans DB Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Front Biosci 3:E193-203, 1998. PMID: 9792895.
- Evans DB, Pisters PW, Lee JE, Bold RJ, Charnsangavej C, Janjan NA, Wolff RA, Abbruzzese JL Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. J Hepatobiliary Pancreat Surg 5(3):242-50, 1998. PMID: 9880770.
- Hannun YA, Obeid LM, Wolff RA The novel second messenger ceramide: identification, mechanism of action, and cellular activity. Adv Lipid Res 25:43-64, 1993. PMID: 8396313.
Editorials
- Wolff RA. Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas: Great Logic, Grim Reality. Ann Surg Oncol 8(10):747-8, 2001. PMID: 11776483.
Abstracts
- Thomas RM, Truty MJ, Fleming JB, Pisters Peter WT, et al. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. ASCO GI Cancers Symposium, 2012. e-Pub 2012.
- Eng C, Blackham AU, Overman MJ, Fournier KF, Royal RE, Gajula P, Levine EA, Wolff RA, et al. Systemic chemotherapy in the setting of unresectable appendiceal epithelial neoplasms (AEN). ASCO GI Cancers Symposium, 2012. e-Pub 2012.
- Raghav KPS, Kazmi SMA, Shetty AV, Taggart MW, et al. Prognostic and predictive effect of COX-2 expression in appendiceal adenocarcinomas. ASCO GI Cancers Symposium, 2012. e-Pub 2012.
- Javle MM, Tan D, Kar YLS, Baladandayuthapani V, et al. Transforming growth factor (TGF) B pathway and clinical outcome of pancreatic cancer. ASCO GI Cancers Symposium, 2012. e-Pub 2012.
- Fogelman DR, Wang XS, Hassan M, Li D, Javle MM, et al. Can we identify cancer patients at high risk for cachexia? A prospective study in pancreatic cancer (PC). ASCO GI Cancers Symposium, 2012. e-Pub 2012.
- Eng C, Overman MJ, Fournier KF, Royal RE, et al. Role of biologic therapy in the treatment of unresectable appendiceal epithelial neoplasms (AEN). ASCO GI Cancers Symposium, 2012. e-Pub 2012.
- Ohinata A, Wallace MJ, Overman MJ, et al WR. The role of partial splenic embolization (PSE) in the management of chemotherapy-induced thrombocytopenia. ASCO GI Cancer Symposium, 2012. e-Pub 2012.
- Overman MJ, Fournier KF, Hu CY, Wolff, RA, et al. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: The prognostic impact of histologic grade. ASCO GI Cancers Symposium, 2012. e-Pub 2012.
- Tzeng CWD, Fleming JB, Lee JE, Xiao L, et al. Use of operability classifications to predict outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. ASCO GI Cancers Symposium, 2012. e-Pub 2012.
- Skinner HD, Javle MM, Wolff RA, et al. Phase I trial of radiotherapy with concurrent bevacizumab, erlotinib, and capecitabine for locally advanced pancreatic cancer (LAPC). ASCO GI Cancers Symposium, 2012. e-Pub 2012.
- Chen Z, Overman MJ, Garrett CR, Jiang ZQ, Wolff RA, et al. Systemic survey of therapeutic trials for metastatic colorectal cancer. ASCO GI Cancers Symposium, 2012. e-Pub 2012.
- Wolff RA, Crane CH, Xiong HQ, et al CK. Preliminary analysis of preoperatie systemic gemcitabine (GEM) and cisplatin (CIS) followed by GEM-based chemoradiation for resectable pancreatic adenocarcinoma, 2004. e-Pub 2004.
- Wolff RA, Crane CH, Xiong HQ, Cleary KR, et al. Preliminary analysis of preoperative systemic gemcitabine (GEM) and cisplatin (CIS) followed by GEM-based chemoradiation for resectable pancreatic adenocarcinoma. ASCO GI Cancers Symposium, 2004. e-Pub 2004.
- Crane CH, Ellis LM, Xiong H, Ho L, O’Reilly M, Evans, DB, Delclos ME, Abbruzzese JL, Charnsangavej C, NG C, Tamm EP, Wolff RA. Preliminary results of a phase I study of rhuMab VEGF (bevacizumab) with concurrent radiotherapy (XRT) and capecitabine (CAP). ASCO GI Cancers Symposium, 2004. e-Pub 2004.
- Tamm EP, Loyer E, Faria S, Wolff RA, Evans DB, Charnsangavej C. Identifying Resectable Pancreatic and Periampullary Adenocarcinoma with Multidetector CT (MDCT). 89th Annual Radiologic Society of North America Scientific Meeting, 2003. e-Pub 2003.
- Hou Z, Elasmar SA, Lozano R, Hoff P, Wolff RA, Abbruzzese JL, Ajani JA, Carr K, Rashid A, Yao JC. A pilot study of irinotecan plus cisplatin in patients with metastatic high grade neuroendocrine carcinoma. ASCO, 2003. e-Pub 2003.
- Wolff RA, Ayers GD, Crane CH, Abbruzzese JL, Janjan NA, Delclos ME, Vauthey JN, Lee E, Pisters PW, Evans DB. Serum CA19-9 levels in patients receiving preoperative gemcitabine (Gem)-based chemoradiation for respectable pancreatic adenocarcinoma. ASCO, 2003. e-Pub 2003.
- Lenzi R, Verschraegen CF, Kudelka AP, Vincent M, Wolff RA, Abbruzese JA, Cristofanilli M, Loyer E, Hu W, Kavanagh JJ, Rubin E. New escalation scheme for phase I study of drug combination: 9-nitro-20(S)-camptothecin (RFS 2000) with cisplatin for patients (pts) with advanced malignancies. ASCO, 2002. e-Pub 2002.
- Wolff RA. Initial Results of Preoperative Gemzar Based Chemoradiation for Resectable Pancreatic Adenocarcinoma. 2002 Lilly Oncology Investigators Meetings, 2002. e-Pub 2002.
- Wolff RA. Management of Hepatic Metastases. ASCO Clinical Practice Forum, 2000. e-Pub 2000.
- Wolff RA. Gemcitabine in GI Malignancies. Second Annual Fall Oncology Conference, Advances in Solid Tumors, 1998. e-Pub 1998.
Book Chapters
- Mizrahi, JD, Wolff, RA. Management of locally advanced/metastatic disease, 97-106, 2022.
- Mizrahi JD, Wolff RA. Management of Locally Advanced/Metastatic Disease: Medical Oncology. In: Pancreatic Cancer: A Multidisciplinary Approach. Springer, 2022.
- Thomas MB, Hoff PM, Wolff RA. Colorectal Cancer. In: M.D. Anderson Manual of Medical Oncology. McGraw Hill, 395-427, 2006.
- Gibbons D, Varadhachary GR, Wolff RA. Targeted Therapy in Pancreatic Cancer. In: Targeted Therapy in Cancer. The Humana Press, 2006.
- Wolff, RA, Crane CH, Li D, Abbruzzese JL, Evans DB. Neoplasms of the Exocrine Pancreas. In: Cancer Medicine. 7th. B.C. Decker, Inc, 1331-1358, 2006.
- Pisters PWT, Evans, DB, Wolff RA, Crane C. Staging and therapeutic approaches for patients with localized, potentially curable pancreatic adenocarcinoma. In: Gastrointestinal Cancer, 184-196, 2005.
- Wolff RA. Adjuvant and neoadjuvant therapies for resectable pancreatic cancer. In: Pancreatic Cancer. Jones and Bartlett, 373-394, 2005.
- Raut CP, Evans DB, Crane CH, Pisters PWT, Wolff RA. Neoadjuvant Therapy for Resectable Pancreatic Cancer. In: Surgical Oncology Clinics of North America, 639-661, 2004.
- Crane C, Evans DB, Wolff RA, Abbruzzese J, Pisters P, Janjan N. The Pancreas. In: Radiation Oncology, 465-480, 2003.
- Yen TWF, Evans DB, Wolff RA. Neoplasms of the ampulla of vater. In: Cancer Medicine. 6. B.C. Decker Inc, 1615-21, 2003.
- Thomas MB Wolff RA. Current Understanding of Colorectal Neoplasia, Part 26. In: Colonic Diseases, 423-439, 2003.
- Evans DB, Wolff RA, Crane CH, Pisters PWT. Combined Modality Treatment for Pancreatic Cancer. In: Progress in Oncology, 250-76, 2003.
- Wolff RA, Abbruzzese JL, Evans DB. Neoplasms of the exocrine pancreas. In: Cancer Medicine. 6. B.C. Decker Inc, 1585-1614, 2003.
- Wolff RA. Exploiting molecular targets in pancreatic cancer. In: Hematology/Oncology Clinics of North America, 139-157, 2002.
- Wolff RA. Cytotoxic Chemotherapy for Pancreatic Cancer: Past, Present, and Future Pancreatic Cancer. In: MD. Anderson Solid Tumor Oncology Series, Part 27, 311-320, 2001.
- Evans, Douglas B, Wolff, RA. Neoplasms of the ampulla of vater. In: Cancer Medicine. B.C. Decker Inc, 1431-35, 2000.
- Wolff, Abbruzzese R, James L, Evans, Douglas B. Neoplasms of the exocrine pancreas. In: Cancer Medicine. 5th. B.C. Decker Inc, 1436-64, 2000.
- Royal RE, Wolff RA, Crane CH. Pancreas Cancer. In: Cancer: Principles and Practice of Oncology. Lippincott, Williams and Wilkins.
Books (edited and written)
- Bhutani MS, Katz MHG, Maitra A, Herman JM, Wolff RA. Pancreatic Cancer: A Multidisciplinary Approach. Springer, 2022.
- Kantarjian HM, Wolff RA. The MD Anderson Manual of Medical Oncology. Ed(s) Third Edition. McGraw-Hill Education, 2016.
- Kantarjian HM, Wolff RA, Koller CA. The MD Anderson Manual of Medical Oncology. Ed(s) Second Edition. The McGraw-Hill Companies, 2011.
- Kantarjian HM, Wolff RA, Koller CA. MD Anderson Manual of Medical Oncology. The McGraw-Hill Companies, 2006.
Letters to the Editor
- Evans DB, Wolff RA, Hess KR. Adjuvant radiotherapy and 5-flourouracil after curative resection of cancer of the pancreas and periampullary region. Annals of Surgery 232: 727, 2000.
- Wolff, RA, Janjan NA, Lenzi R, Abbruzzese J, Goswitz, M, Charnsangavej C, Pisters P, Lee J, Evans D. Treatment Related Toxicities with Rapid-Fractionation External Beam Radiation Therapy and Concomitant Gemcitabine for Locally Advanced Nonmetastatic Adenocarcinoma of the Pancreas. Radiation Oncology Biology Physics 42, 1998.
Selected Presentations & Talks
Regional Presentations
- 2017. Pancreatic Cancer - Moderator. Conference. MD Anderson Cancer Center, TX, US.
- 2017. Pancreatic Cancer - Section Moderator. Conference. MD Anderson Cancer Center, TX, US.
- 2015. Cancer, MD Anderson and the Moon. Conference. Queen's Joint Board Retreat. Honolulu, HI, US.
- 2013. Management of Bordeline Resectable Pancreatic Cancer. Conference. London Health Sciences Center. London, Ontario, CA.
- 2013. Dosing Chemotherapy for GI Malignancies: What Evidence Do We Have? 10th Oncology Update: Advances and Controversies. Conference. The University of Texas MD Anderson Cancer Center. Steamboat Spring, CO, US.
- 2012. Pancreatic Cancer 2012: A Clinician's View. Conference. The University of Kansas Medical Center. Kansas City, KS, US.
- 2012. Update in the Management of Cancers of the Pancreas, Hepatobiliary Tract and Neuroendocrine Tumors. Conference. The University of Kansas Medical Center. Kansas City, KS, US.
- 2012. Best of ASCO 2011. Conference. Association of Cancer Executives. Savannah, GA, US.
- 2012. Systemic Therapy for High-Risk and Metastatic Colorectal Cancer: Integration of Molecular Analyses. Conference. The University of Texas, MD Anderson Cancer Center. Steamboat Springs, CO, US.
- 2012. Systemic Therapy for Pancreas Cancer: Are We Making Progress. Conference. The University of Texas, MD Anderson Cancer Center. Steamboat Springs, CO, US.
- 2011. Emerging Trends in Pancreatic Cancer. Conference. CR Wood Cancer Center. Glen Falls, NY, US.
- 2011. Borderline Resectable Pancreatic Cancer. Conference. ProMedica Health System Cancer Institute. Sylvania, OH, US.
- 2010. Pancreatic Cancer 2010: A Clinician's View. Conference. University of Cincinnati. Cincinnati, OH, US.
- 2010. Is R1 or R2 Resection of Pancreatic Adenocarcinoma of any Benefit or Does It Just Increase Morbidity?. Conference. St. Louis University. St. Louis, MO, US.
- 2010. Treatments for Pancreatic Cancer. Conference. Pancreatic Cancer Action Network. Dallas, TX, US.
- 2010. Neoadjuvant and Adjuvant chemotherapy: Why and How. Conference. The University of Cincinnati Medical Center. Cincinnati, OH, US.
- 2009. Controversies in the Management of Pancreatic Cancer. Conference. Medical College of Wisconsin. Milwaukee, WI, US.
- 2009. New Therapies for Pancreatic Cancer and What's on the Horizon?. Conference. Medical College of Wisconsin. Milwaukee, WI, US.
- 2009. Neo-Adjuvant and Adjuvant Therapy for Pancreatic Cancer. Conference. Greenville Hospital System University Medical Center. Greenville, SC, US.
- 2008. Management of Pancreatobiliary Malignancies. Conference. St. Louis University Cancer Center. St. Louis, MO, US.
- 2008. Multidisciplinary Management of Advanced Colorectal Cancer. Conference. The University of Texas, MD Anderson Cancer Center. Boston, MA, US.
- 2008. Adjuvant Treatment of Pancreatic Cancer. Conference. The University of Texas, MD Anderson Cancer Center. Boston, MA, US.
- 2008. Management of Upper GI Malignancies. Conference. Hoag Cancer Center. Northport Beach, CA, US.
- 2008. Preoperative Therapy for Localized Operable Pancreas Cancer. Conference. MD Anderson Cancer Center-Orlando. Orlando, FL, US.
- 2008. Multidisciplinary Care of the Patient with Colorectal Cancer. Conference. The University of Texas, MD Anderson Cancer Center. Park City, UT, US.
- 2007. Management of Advanced Pancreatic Cancer: An Update. Conference. University of Louisville. Louisville, KY, US.
- 2007. Multimodality Management fo Colorectal Cancer. Conference. Duke School of Medicine. Virginia Beach, VA, US.
- 2007. Have We Made Any Progress in Treating Pancreatic Cancer. Conference. The University of Texas, MD Anderson Cancer Center. Santa Barbara, CA, US.
- 2007. Update on Adjuvant Chemotherapy for Colorectal Cancer. Conference. The University of Texas, MD Anderson Cancer Center. Santa Barbara, CA, US.
- 2007. Decision Making in Medical Therapy for Metastatic Colorectal Cancer. Conference. The University of Texas, MD Anderson Cancer Center. Santa Barbara, CA, US.
- 2007. Emerging Strategies in the Management of Advanced Colorectal Cancer. Conference. Oklahoma Society of Clinical Oncology (OSCO). Oklahoma City, OK, US.
- 2007. Case Presentations on Pancreas/Liver. Conference. The University of Texas, MD Anderson Cancer Center. Steam Boat Springs, CO, US.
- 2006. Gemcitabine/Oxaliplatin Combinations in Locally Advanced Pancreatic Cancer. Conference. Chemotherapy Foundation. New York, NY, US.
- 2006. Pancreatic Cancer: What is new on adjuvant therapy and treatment of advanced disease. Conference. Aultman Cancer Center. Canton, OH, US.
- 2005. Current Management Strategies of Pancreatic Cancer. Conference. Unknown. Philadelphia, PA, US.
- 2005. Emerging Treatment Strategies for Localized Pancreatic Cancer. Conference. Medical University of South Carolina. Charleston, SC, US.
- 2005. The Science of Pancreatic Cancer. Conference. PANCAN, TX, US.
- 2005. State of the Art: Targeted Therapies for Pancreatic Cancer. Conference. Memorial Sloan Kettering Cancer Center. New York, NY, US.
- 2005. Adjuvant and Neoadjuvant Therapy. Conference. The University of Texas, MD Anderson Cancer Center. Hyannis Port, MA, US.
- 2005. Non-Surgical Treatment for Pancreatic Cancer: Current Knowledge and Future Direction. Conference. East Texas Medical Center. Tyler, TX, US.
- 2005. Chemotherapy. Conference. The University of Texas, MD Anderson Cancer Center. Park City, UT, US.
- 2004. Neoadjuvant Chemotherapy for Pancreatic Cancer. Conference. The University of Texas, MD Anderson Cancer Center. Kauai, HI, US.
- 2004. Novel Treatment Strategies for Resectable Pancreatic Cancer. Conference. The University of Texas, MD Anderson Cancer Center. Steamboat, CO, US.
- 2003. Targeted Agents in Colorectal Cancer. Conference. Unknown. Orlando, FL, US.
- 2003. Treatment Regimens for Pancreatic Cancer. Conference. Rush University. Chicago, IL, US.
- 2003. Updates in the Solid Tumors & Established Molecular Therapies. Conference. The University of Texas, MD Anderson Cancer Center. Austin, TX, US.
- 2003. Cancers of the Colon and Rectum: Emerging Strategies with Oral Fluoropyrimidines. Conference. Unknown. Denver, CO, US.
- 2003. Adjuvant Treatment of Stage II Colon Cancer. Conference. The University of Texas, MD Anderson Cancer Center. Steamboat Springs, CO, US.
- 2002. Are Patients with cancer receiving adequate thromboprophylaxis?. Conference. Pharmacia. Philadelphia, PA, US.
- 2002. Pancreatic Cancer: Treatment Options. Conference. Wake Forest University. Atlanta, GA, US.
- 2002. Contemporary Approaches to the Management of Pancreatic Cancer. Conference. St. Joseph Mercy Oakland. Troy, MI, US.
- 2002. Meeting the Challenge of Cancer in Thrombosis Patients. Conference. Unknown. Boston, MA, US.
- 2002. Looking Ahead: Prevention, Treatment, Patient Compliance, and the Policies that Affect Them Cancer. Conference. Cancer Research Foundation of America. Bethesda, MD, US.
- 2002. Current and Novel Therapies for Pancreatic Cancer. Conference. Unknown. Maui, HI, US.
- 2002. Current Trends in Pancreatic Cancer Therapy. Conference. University of Virginia. Charlottesville, VA, US.
- 2002. Systemic Therapy for Pancreatic Cancer. Conference. The University of Texas, MD Anderson Cancer Center. Steamboat Springs, CO, US.
- 2001. Pancreatic Cancer. Conference. Unknown. Pensacola, FL, US.
- 2001. New Approaches to Old Problems in Cancer Management. Conference. Unknown. Dallas, TX, US.
- 2000. Contemporary Issues in Diagnosis and Treatment of Colorectal Cancer. Conference. Nevada Oncology Society. Las Vegas, NV, US.
- 1999. Adjuvant Therapy and Newer Agents in the Treatment of Colorectal Cancer. Conference. Unknown. Toledo, OH, US.
- 1999. Current and Future Strategies in the Management of Pancreatic Adenocarcinoma-The Role of Chemotherapy in Pancreatic Carcinoma. Conference. Unknown. Amelia Island, FL, US.
- 1999. Current Management and Future Direction for Pancreatic Cancer. Conference. University of New Mexico. Albuquerque, NM, US.
- 1999. Xeloda - Unknown Topic or Presentation. Conference. Roche. Suffern, NY, US.
- 1998. Treatment Modalities of Pancreatic or Head and Neck Cancer. Conference. St. Louis University. St. Louis, MO, US.
- 1998. Gemcitabine in GI Malignancies. Conference. Unknown. Hilton Head, SC, US.
National Presentations
- 2020. Hepatobiliary Cancers with Focus on Biliary Tract Tumors/ Introduction to cholangiocarcinoma general approach to disease with discussion of a newer sytotoxic regimen and potential for molecular therapeutics. Invited. 18th Oncology Update: Advances and Controversies. Steamboats Springs, CO, US.
- 2016. Advances and Controversies: Systemic Therapy for Resectable Pancreas Cancer: Adjuvant or Neo-adjuvant?. Conference. 14th Oncology Update. Steamboat Springs, CO, US.
- 2015. Borderline Resectable Pancreatic Cancer. Invited. Society of Surgical Oncology. Houston, TX, US.
- 2014. Updates in the Management of Pancreatic Cancer: Challenges and Opportunities in Management of 'Localized' Pancreatic Cancer. Conference. St. John Providence Health System. Grosse Pointe, MI, US.
- 2014. Global Academic Programs 2014: Pancreatic-Billiary Cancer: Pancreatic Cancer - New Strategies for a Changing Disease. Invited. Sister Institute: Yonsei Cancer Institute. Seoul.
- 2011. A double-blind, randomized placebo-controlled, phase II study of maintenance enzastaurin (ENZ) with 5-FU/leucovorin (LV) plus bevacizumab (BV) following first-line therapy for metastatic colorectal cancer (mCRC). Conference. Lilly. San Francisco, CA, US.
- 2010. Upfront Surgical Resection or Preoperative Therapy: Who for What?. Conference. 63rd Annual Cancer Symposium. St. Louis, MO, US.
- 2007. Use of Targeted Agents and Sequencing Treatment for Pancreatic Cancer. Conference. American College of Surgeons 93rd Annual Clinical Congress. New Orleans, LA, US.
- 1998. Treatment Related Toxicities with Rapid-Fractionation External Beam Radiation Therapy and Concomitant Gemcitabine for Locally Advanced Nonmetastatic Adenocarcinoma of the Pancreas. Conference. ASTRO’s 40th Annual Meeting, US.
International Presentations
- 2022. Update in the Management of Pancreatic Cancer (neoadjuvant and adjuvant and METS) The Use of Liquid Biopsy to Guide Adjuvant Therapy in CRC. Invited. The 3rd Emirates Oncology Society Annual Conference. Dubai, AE.
- 2021. Pancreatic Cancer 2021: Emerging Efforts in Detection, Standard Therapies and Precision Medicine. Invited. The 2nd EOS Annual Conference, AE.
- 2020. 8th International Oncology Conference: Working Together to Improve Cancer Care - Colorectal Cancer Systemic Therapy Update. Invited. International Oncology Conference 2020/ VIRTUAL, AE.
- 2020. GI Colorectal Cancer: Updates in the Management of Colorectal Cancer. Invited. EOS Annual Conference 2020/ VIRTUAL, AE.
- 2019. Pancreatic Tumors - Multidisciplinary Tumor Board Panel: Medical Oncology (Expert Discussant). Invited. 2nd MD Anderson International Meeting in Gastrointestinal Oncology: Current Practice and Controversies in the Era of Personalized Medicine. Madrid, ES.
- 2019. Is Neoadjuvant Therapy needed in Resectable Pancreatic Cancer? (Debate). Invited. 2nd MD Anderson International Meeting in Gastrointestinal Oncology: Current Practice and Controversies in the Era of Personalized Medicine. Madrid, ES.
- 2019. Immunotherapy in Pancreatic Cancer. Invited. 2nd MD Anderson International Meeting in Gastrointestinal Oncology: Current Practice and Controversies in the Era of Personalized Medicine. Madrid, ES.
- 2017. Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer - Keynote Speaker. Invited. Emirates Oncology Conference 2017, AE.
- 2016. Innovative Approaches to Hepatopanceatobiliary Diseases (ARS): Pro: Neoadjuvant Therapy. Conference. ASCO 2016 Gastrointestinal Cancers Symposium. San Francisco, US.
- 2011. A double-blind, randomized, placebo-controlled, phase II study of maintenance enzastaurin with 5-FU/leucovorin plus bevacizumab following first-line therapy for metastatic colorectal cancer (mCRC). Invited. Lilly. Chicago, US.
- 2011. The Business of Running a Training Program - Microeconomics. Invited. 2011 ASCO Training Program Directors Special Session. Chicago, US.
- 2009. Management of Borderline Resectable Pancreatic Cancer. Invited. ASCO 2009 Gastrointestinal Cancers Symposium. San Francisco, US.
- 2008. Educational and Training System of Medical Oncologists in USA. Invited. 46th Annual Meeting of Japan Society of Clinical Oncology. Tokyo, JP.
- 2008. Scientific / Oral Presentation Discussant on Pancreatic Cancer. Conference. 44th ASCO Annual Meeting. Chicago, US.
- 2008. Targeted Therapy in Pancreatic Cancer: The Basics. Conference. Pancreas Cancer Conference 2008. Trigoria, IT.
- 2008. Emerging Therapeutic Strategies for Pancreatic Cancer. Conference. Thai Physicians Association of America (TPAA) and Ramathibodi School of Medicine Annual Scientific Meeting. Bankok, TH.
- 2005. Controversies in the Use of Adjuvant Therapy for Patients with Pancreatic Cancer Session Chair. Conference. ASCO 41st Annual Meeting. Orlando, US.
- 2005. Targeted Therapies in Pancreatic Cancer. Invited. ASCO 2005 Gastrointestinal Cancers Symposium. Hollywood, US.
- 2004. Pancreatic Cancer and Gemcitabine. Conference. Joint Meeting of the International Association of Pancreatology and Japan Pancreas Society. Sendai, JP.
- 2004. Randomized Controlled Study for Pancreatic Cancer. Conference. Joint Meeting of the International Association of Pancreatology and Japan Pancreas Society. Sendai, JP.
- 2003. Adjuvant Therapy for Resectable Pancreatic Cancer: Preoperative and Postoperative Approaches. Invited. 10th International Conference on Gastrointestinal Cancer: Hepatobiliary and Pancreatic Cancer. Williamsburg, US.
- 2002. Initial Results of preoperative gemcitabine (GEM)-based chemoradiation for respectable pancreatic adenocarcinoma. Conference. 2002 ASCO Annual Meeting Oral Presentation. Orlando, US.
Formal Peers
- 2024. Pancreaticobiliary Cancers/Unknown Primary. Visiting. MD Anderson Cancer Center and Baylor College of Medicine. Houston, TX, US.
- 2018. Controversies in Neoadjuvant Therapy Bordeline Resectable and Locally Advanced Pancreatic Cancer: Role of the Medical Oncologist. Invited. Society of Surgical Oncology, US.
- 2007. Emerging Strategies for Borderline Resectable Pancreatic Cancer. Visiting. Johns Hopkins School of Medicine. Baltimore, MD, US.
- 2007. Pancreatic Cancer. Visiting. Johns Hopkins School of Medicine. Baltimore, MD, US.
Grant & Contract Support
| Date: | 2021 - 2028 |
| Title: | 2021-0502-A Multicenter, Open-label, Exploratory Platform Trial to Evaluate Immunotherapy Combinations with Chemotherapy for Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma (Protocol #PICI0044) |
| Funding Source: | Parker Institute for Cancer |
| Role: | PI |
| ID: | 2021-0502 | PID12937 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | Elsa U. Pardee Foundation Fund for Medical Oncology Fellowship Training |
| Role: |
Patient Reviews
CV information above last modified April 15, 2025